Abstract
Various criteria used to define atypical antipsychotic drugs include: 1) decrease, or absence, of the capacity to cause acute extrapyramidal motor side effects (acute EPSE) and tardive dyskinesia (TD); 2) increased therapeutic efficacy reflected by improvement in positive, negative, or cognitive symptoms; 3) and a decrease, or absence, of the capacity to increase prolactin levels. The pharmacologic basis of atypical antipsychotic drug activity has been the target of intensive study since the significance of clozapine was first appreciated. Three notions have been utilized conceptually to explain the distinction between atypical versus typical antipsychotic drugs: 1) dose-response separation between particular pharmacologic functions; 2) anatomic specificity of particular pharmacologic activities; 3) neurotransmitter receptor interactions and pharmacodynamics. These conceptual bases are not mutually exclusive, and the demonstration of limbic versus extrapyramidal motor functional selectivity is apparent within each arbitrary theoretical base. This review discusses salient distinctions predominantly between prototypic atypical and typical antipsychotic drugs such as clozapine and haloperidol, respectively. In addition, areas of common function between atypical and typical antipsychotic drug action may also be crucial to our identification of pathophysiological foci of the different dimensions of schizophrenia, including positive symptoms, negative symptoms, and neurocognitive deficits.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ackenheil M, Hippius H (1977) Clozapine. In: Usdin E, Forrest IS (eds) Psychotherapeutic drugs. Part II Marcel Dekker, New York, pp 923–956
Ackenheil M, Blatt B, Lampart C (1974) Biochemical changes in man and animal following clozapine treatment. J Pharmacol (Paris) 5 [Suppl 2]:1
Aguilar MA, Minarro J, Pereziranzo N, Simon VM (1994) Behavioral profile of raclopride in agonistic encounters between male mice. Pharmacol Biochem Behav 47:753–756
Ahlfors UG, Rimon R, Appelberg B, Hagert U, Harma P, Katila H, Mahlanen A, Mehtonen OP, Naukkarinen H, Outakoski J (1990) Remoxipride and haloperidol in schizophrenia: a double-blind multicentre study. Acta Psychiatr Scand Suppl 358:99–103
Akai T, Yamaguchi M, Mizuta E, Kuno S (1993) Effects of terguride, a partial D2 agonist, on MPTP-lesioned parkinsonian cynomolgus monkeys. Ann Neurol 33:507–511
Alekhina TA, Gilinskii MA, Kolpakov VG (1995) [The level of catecholamines and dihydroxyphenylacetic acid in the brain of rats with a hereditary predisposition to catalepsy]. Zh Vyssh Nerv Deiat Im I P Pavlova 45:180–184
Altar CA, Boyar WC, Wasley A, Gerhardt SC, Liebman JM, Wood PL (1988) Dopamine neurochemical profile of atypical antipsychotics resembles that of D-1 antagonists. Naunyn Schmiedebergs Arch Pharmacol 338:162–168
Anden NE, Stock G (1973) Effect of clozapine on the turnover of dopamine in the corpus striatum and in the limbic system. J Pharm Pharmacol 25:346–348
Andersen J, Korner A, Ostergaard P, Fensbo C, Birket-Smith M, Thiesen S, Hansen NR, Fogh M, Kristensen M, Moller-Nielsen EM (1990) A double blind comparative multicentre study of remoxipride and haloperidol in schizophrenia. Acta Psychiatr Scand Suppl 358:104–107
Anderson GD, Rebec GV (1988) Clozapine and haloperidol in the amygdaloid complex: differential effects on dopamine transmission with long-term treatment. Biol Psychiatry 23:497–506
Andreasen NC, Rezai K, Alliger R, Swayze VW 2d, Flaum M, Kirchner P, Cohen G, O'Leary DS (1992) Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the Tower of London. Arch Gen Psychiatry 49:943–958
Antelman SM, Caggiula AR (1977) Norepinephrine-dopamine interactions and behavior. Science 195:646–653
Antoniou K, Kafetzopoulos E (1992) Behavioral effects of amphetamine and apomorphine after striatal lesions in the rat. Pharmacol Biochem Behav 43:705–722
Arana GW, Ornsteen ML, Kanter F, Friedman HL, Greenblatt DJ, Shader RI (1986) The use of benzodiazepines for psychotic disorders: a literature review and preliminary clinical findings. Psychopharmacol Bull 22:77–87
Arevalo GJ, Gershanik OS (1993) Modulatory effect of clozapine on levodopa response in Parkinson's disease: a preliminary study. Move Disord 8:349–354
Arnold G, Trenkwalder C, Schwarz J, Oertel WH (1994) Zotepine reversibly induces akinesia and rigidity in Parkinson disease patients with resting tremor or drug-induced psychosis. Move Disord 9:238–240
Arnt J, Hyttel J, Bach-Lauritsen T (1986) Further studies of the mechanism behind scopolamine-induced reversal of antistereotypic and cataleptogenic effects of neuroleptics in rats. Acta Pharmacol Toxicol (Copenh) 59:319–324
Asghari V, Schoots O, Vankats S, Ohara K, Jovanovic V, Guan HC, Bunzow JR, Petronis A, Van Tol HHM (1994) Dopamine D4 receptor repeat: analysis of different native and mutant forms of the human and rat genes. Mol Pharmacol 46:364–373
Ashby CR Jr, Wang RY (1990) Effect of antipsychotic drugs on 5-HT2 receptors in the medial prefrontal cortex: microiontophoretic studies. Brain Res 506:346–348
Ashby CR Jr, Minabe Y, Edwards E, Wang RY (1991) Comparison of the effects of various typical and atypical antipsychotic drugs on the suppressant action of 2-methylserotonin on medial prefrontal cortical cells in the rat. Synapse 8:155–161
Assie MB, Sleight AJ, Koek W (1993) Biphasic displacement of [3H]YM-09151-2 binding in the rat brain by thioridazine, risperidone and clozapine, but not by other antipsychotics. Eur J Pharmacol 237:183–189
Auchus AP, Pickel VM (1992) Quantitative light microscopic demonstration of increased pallidal and striatal met5-enkephalin-like immunoreactivity in rats following chronic treatment with haloperidol but not with clozapine: implications for the pathogenesis of neuroleptic-induced movement disorders. Exp Neurol 117:17–27
Auff E, Birkmayer W, Brucke T, Deecke L, Emich C, Goldenberg G, Hirsch E, Maly J, Muller C, Potzl G, Riederer P, Sofic E, Schnaberth G (1987) Ritanserin in the treatment of tremordominant Parkinson's disease: a preliminary study. New Trends Clin Neuropharmacol 1:149–158
Awad G, Hogan TP (1994) Subjective response to neuroleptics and the quality of life - implications for treatment outcome. Acta Psychiatr Scand 89 [Suppl. 380]:27–32
Awouters F, Niemegeers CJE, Megens AAHP, Meert TF, Janssen PAJ (1988) Pharmacological profile of ritanserin: a very specific central serotonin S2 antagonist. Drug Dev Res 15:61–73
Baldessarini RJ, Frankenburg FR (1991) Clozapine. A novel antipsychotic agent. N Engl J Med 324:746–754
Balsara JJ, Jadhav JH, Chandorkar AG (1979) Effect of drugs influencing central serotonergic mechanisms on haloperidol-induced catalepsy. Psychopharmacology 62:67–69
Banerjee U, Sooi Lin G (1973) On the mechanism of central action of amphetamine: the role of catecholamines. Neuropharmacology 12:917–931
Bardgett ME, Wrona CT, Newcomer JW, Csernansky JG (1993) Subcortical excitatory amino acid levels after acute and subchronic administration of typical and atypical neuroleptics. Eur J Pharmacol 230:245–250
Barr CL, Kennedy JL, Lichter JB, Vantol HHM, Wetterberg L, Livak KJ, Kidd KK (1993) Alleles at the dopamine D-4 receptor locus do not contribute to the genetic susceptibility to schizophrenia in a large Swedish kindred. Am J Med Genet 48:218–222
Bartholini G (1976) Differential effect of neuroleptic drugs on dopamine turnover in the extrapyramidal and limbic system. J Pharm Pharmacol 28:429–433
Bartholini G, Haefely W, Jalfre M, Keller HH, Pletscher A (1972) Effects of clozapine on cerebral catecholaminergic neurone systems. Br J Pharmacol 46:736–740
Bartholini G, Keller HH, Pletscher A (1973) Effect of neuroleptics on endogenous norepinephrine in rat brain. Neuropharmacology 12:751–756
Beasley CM, Tollesfson GD, Tye ND, Moore NA (1993) Olanzapine: a potential “atypical” antipsychotic agent. Presented at the 32nd Annual Meeting of the American College of Neuropsychopharmacology, Hawaii
Benkert O, Wetzel H, Wiedemann K (1990) Dopamine autoreceptor agonists in the treatment of positive and negative schizophrenia. In: Yamachita I, Toru M, Coppen AJ (eds) Clinical neuropharmacology: proceedings from the 17th CINP Congress. Raven Press, New York, pp 178–179
Bennett JP, Landow ER, Schuh LA (1993) Suppression of dyskinesias in advanced Parkinson's disease. II. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms. Neurology 43:1551–1555
Berman KF, Torrey EF, Daniel DG, Weinberger DR (1992) Regional cerebral blood flow in monozygotic twins discordant and concordant for schizophrenia. Arch Gen Psychiatry 49:927–934
Bersani G, Grispini A, Marini S, Pasini A, Valducci M, Ciani N (1986) Neuroleptic-induced extrapyramidal side effects: clinical perspectives with ritanserin (R 55667), a new selective 5-HT2 receptor blocking agent. Curr Ther Res 40:492–499
Bersani G, Grispini A, Marini S, Pasini A, Valducci M, Ciani N (1990) 5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo. Clin Neuropharmacol 13:500–506
Bersani G, Venturi P, Tanfani G, Pancheri P (1995) Cerebral ventricular enlargement and neuroleptic response in chronic schizophrenia: preliminary findings with risperidone. Hum Psychopharmacol Clin Exp 10:53–58
Biazzi A, Fregnan GB (1980) Behavioral, anti-dopaminergic, and prohypnotic effects of neuroleptics during and after prolonged treatment. Adv Biochem Psychopharmacol 24:351–357
Blaha CD, Lane RF (1987) Chronic treatment with classical and atypical antipsychotic drugs differentially decreases dopamine release in striatum and nucleus accumbens in vivo. Neurosci Lett 78:199–204
Bluth R, Langnickel R, Ott T (1985) Modulation by dopaminergic and serotonergic systems of cholinergic interneurons in nucleus accumbens and striatum. Pol J Pharmacol Pharm 37:753–763
Bluth R, Langnickel R (1985) Effects of haloperidol and low dose clozapine on the acetylcholine turnover rate in rat forebrain structures. Biomed Biochim Acta 44:1531–1539
Bolden-Watson C, Watson MA, Murray KD, Isackson PJ, Richelson E (1993) Haloperidol but not clozapine increases neurotensin receptor mRNA levels in rat substantia nigra. J Neurochem 61:1141–1143
Borenstein P, Bles G (1965) Effets cliniques et electroencephalographiques du metoclopramide en psychiatrie. Therapie 20:975–995
Borison RL, Pathiraja AP, Diamond BI, Meibach RC (1992) Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 28:213–218
Bourdelais AJ, Deutch AY (1994) The effects of haloperidol and clozapine on extracellular GABA levels in the prefrontal cortex of the rat - an in vivo microdialysis study. Cereb Cortex 4:69–77
Bowers MB, Rozitis A (1974) Regional differences in homovanillic acid concentration after acute and chronic anministration of antipsychotic drugs. J Pharm Pharmacol 26:743–745
Bowery B, Rothwell LA, Seabrook GR (1994) Comparison between the pharmacology of dopamine receptors mediating the inhibition of cell firing in rat brain slices through the substantia nigra pars compacta and ventral tegmental area. Br J Pharmacol 112:873–880
Boyson SJ, McGonigle P, Luthin GR, Wolfe BB, Molinoff PB (1988) Effects of chronic administration of neuroleptic and anticholinergic agents on densities of D2 dopamine and muscarinic cholinergic receptors in rat striatum. J Pharmacol Exp Ther 244:987–993
Breier A, Buchanan RW, Elkashef A, Munson RC, Kirkpatrick B, Gellad F (1992) Brain morphology and schizophrenia. A magnetic resonance imaging study of limbic, prefrontal cortex, and caudate structures. Arch Gen Psychiatry 49: 921–926
Breier A, Buchanan RW, Waltrip RW, Bryant NL, Goldstein DS (1993) Clozapine's superior efficacy is related to its noradrenergic properties. Soc Neurosci Abstr 19: 856
Breier A, Buchanan RW, Waltrip RW 2nd, Listwak S, Holmes C, Gold stein DS (1994) The effect of clozapine on plasma norepinephrine — relationship to clinical efficacy. Neuropsychopharmacology 10: 1–7
Britton DR, Curzon P, Yahiro L, Buckley M, Tufano M, Nadzan A (1992) Evaluation of a stable CCK agonist (A68552) in conditioned avoidance responding in mice, rats, and primates: comparison with typical and atypical antipsychotics. Pharmacol Biochem Behav 43: 369–376
Brougham LR, Conway PG, Ellis DB (1991) Effect of ritanserin on the interaction of amfonelic acid and neuroleptic-induced striatal dopamine metabolism. Neuropharmacology 30: 1137–1140
Buchanan RW, Holstein C, Breier A (1994) The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry 36: 717–725
Buckland PR, Odonovan MC, Mcguffin P (1993) Clozapine and sulpiride up-regulate dopamine-D(3) receptor messenger RNA levels. Neuropharmacology 32: 901–907
Bunney BS (1992) Clozapine: a hypothesised mechanism for its unique clinical profile. Br J Psychiatry Suppl 17: 17–21
Burki HR (1979) Biochemical methods for predicting the occurrence of tardive dyskinesia. Commun Psychopharmacol 3: 7–15
Burki HR, Sayers AC, Ruch W, Asper H (1975) Clozapine and the dopamine hypothesis of schizophrenia, a critical appraisal. Pharmacopsychiatry 8: 115–121
Burt DK, Hungerford SM, Crowner ML, Baez LA (1982) Postnatal development of a cholinergic influence on neuroleptic-induced catalepsy. Pharmacol Biochem Behav 16: 533–540
Busatto GF, Pilowsky LS, Costa DC, Ell PJ, Verhoeff NPLG, Kerwin RW (1995) Dopamine D-2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride — An I-123-IBZN single photon emission tomography (SPET) study. Psychopharmacology 117: 55–61
Calderon SF, Sanberg PR, Norman AB (1988) Quinolinic acid lesions of rat striatum abolish D1- and D2-dopamine receptormediated catalepsy. Brain Res 450: 403–407
Campion D, d'Amato T, Bastard C, Laurent C, Guedj F, Jay M, Dollfus S, Thibaut F, Petit M, Gorwood P et al (1994) Genetic study of dopamine D1, D2, and D4 receptors in schizophrenia. Psychiatry Res 51: 215–230
Carlsson A (1988a) The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1: 179–186
Carlsson A (1988b) Dopamine autoreceptors and schizophrenia. In: Sen AK, Lee T (eds) Receptors and ligands in psychiatry. Cambridge University Press, Cambridge, pp 1–10
Carlsson ML (1993) Are the disparate pharmacological profiles of competitive and un-competitive NMDA antagonists due to different baseline activities of distinct glutamatergic pathways? (hypothesis). J Neural Transm [Gen Sect] 94: 1–10
Carlsson ML, Engberg G, Carlsson A (1994) Effects of D-cycloserine and (+)-HA-966 on the locomotor stimulation induced by NMDA antagonists and clonidine in monoamine-depleted mice. J Neural Transm [Gen Sect] 95: 223–233
Carter CJ, Pycock CJ (1978) Studies on the role of catecholamines in the frontal cortex. Br J Pharmacol 62: 402P
Cascella NG, Macciardi F, Cavallini C, Smeraldi E (1994)d-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia — an open-label study. J Neural Transm [Gen Sect] 95: 105–111
Casey DE (1989a) Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 99 [Suppl]: S47-S53
Casey DE (1989b) Serotonergic aspects of acute extrapyramidal syndromes in nonhuman primates. Psychopharmacol Bull 25: 457–459
Casey DE (1992a) Dopamine D1 (SCH 23390) and D2 (haloperidol) antagonists in drug-naive monkeys. Psychopharmacology 107: 18–22
Casey DE (1992b) The effect of 8-OH-DPAT on haloperidol-induced dystonia in nonhuman primates. Presentedat ACNP, 31st Ann Meeting, San Juan, PR
Casey DE (1993) Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in nonhuman primates. Psychopharmacology 112 [1 Suppl]: S55-S59
Casey DE (1994) Motor and mental aspects of acute extrapyramidal Syndromes. Acta Psychiatr Scand 89 [Suppl. 380]: 14–20
Ceskova E, Svestka J (1993) Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry 26: 121–124
Ceulemans DL, Gelders YG, Hoppenbrouwers ML, Reyntjens AJ, Janssen PA (1985) Effect of serotonin antagonism in schizophrenia: a pilot study with setoperone. Psychopharmacology 85: 329–332
Chacko RC, Hurley RA, Jankovic J (1993) Clozapine use in diffuse Lewy body disease. J Neuropsychiatr Clin Neurosci 5: 206–208
Chakos MH, Lieberman JA, Bilder RM, Borenstein M, Lerner G, Bogerts B, Wu H, Kinon B, Ashtari M (1994) Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. Am J Psychiatry 151: 1430–1436
Chakos MH, Lieberman JA, Alvir J, Bilder R, Ashtari M (1995) Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine. Lancet 345: 456–457
Chakrabarti JK, Horsman L, Hotten TM, Pullar IA, Tupper DE, Wright FC (1980) 4-Piperaziny1-10H-thieno[2, 3-b][1, 5]benzodiazepines as potential neuroleptics. J Med Chem 23: 878–884
Chen JP, Paredes W, Gardner EL (1991a) Chronic treatment with clozapine selectively decreases basal dopamine release in nucleus accumbens but not in caudate-putamen as measured by in vivo brain microdialysis: further evidence for depolarization block. Neurosci Lett 122: 127–131
Chen JP, van Praag HM, Gardner EL (1991b) Activation of 5-HT3 receptor by 1-phenylbiguanide increases dopamine release in the rat nucleus accumbens. Brain Res 543: 354–357
Chen JP, Paredes W, van Praag HM, Gardner EL (1992a) Serotonin denervation enhances responsiveness of presynaptic dopamine efflux to acute clozapine in nucleus accumbens but not in caudate-putamen. Brain Res 582: 173–179
Chen JP, Paredes W, Van Praag HM, Lowinson JH, Gardner EL (1992b) Presynaptic dopamine release is enhanced by 5-HT3 receptor activation in medial prefrontal cortex of freely moving rats. Synapse 10: 264–266
Chen JP, Ruan D, Paredes W, Gardner EL (1992c) Effects of acute and chronic clozapine on dopaminergic function in medial prefrontal cortex of awake, freely moving rats. Brain Res 571: 235–241
Chiodo LA, Bunney BS (1983) Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 3: 1607–1619
Chiodo LA, Bunney BS (1985) Possible mechanisms by which repeated clozapine administration differentially affects the activity of two subpopulations of midbrain dopamine neurons. J Neurosci 5: 2539–2544
Chipkin RE, Latranyi MB (1987) Similarity of clozapine and SCH 23390 in reserpinized rats suggests a common mechanism of action. Eur J Pharmacol 136: 371–375
Choudhary MS, Craigo S, Roth BL (1992) Identification of receptor domains that modify ligand binding to 5-hydroxytryptamine2 and 5-hydroxytryptamine1c serotonin receptors. Mol Pharmacol 42: 627–633
Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W (1993) A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13: 25–40
Christensen AV, Arnt J, Hyttel J, Larsen JJ, Svendsen O (1984) Pharmacological effects of a specific dopamine D-1 antagonist SCH 23390 in comparison with neuroleptics. Life Sci 34: 1529–1540
Claus A, Bollen J, De Cuyer H, Eneman M, Malfroid M, Peuskens J, Heylen S (1992) Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 85: 295–305
Cohen BM, Lipinski JF (1986) In vivo potencies of antipsychotic drugs in blocking alpha 1 noradrenergic and dopamine D2 receptors: implications for drug mechanisms of action. Life Sci 39: 2571–2580
Cohen BM, Keck PE, Satlin A, Cole JO (1991) Prevalence and severity of akathisia in patients on clozapine. Biol Psychiatry 29: 1215–1219
Conley RR, Schulz SC, Baker RW, Collins JF, Bell JA (1988) Clozapine efficacy in schizophrenic nonresponders. Psychopharmacol Bull 24: 269–274
Conley R, Wong D, Tamminga C (1993) Striatal receptor occupancy with clozapine versus haloperidol in schizophrenia using pet with 11C-NMSP. Soc Neurosci Abstr 19: 857
Costall B, Naylor RJ (1975) Detection of the neuroleptic properties of clozapine, sulpiride and thioridazine. Psychopharmacologia 43: 69–74
Costall B, Naylor RJ (1976a) A comparison of the abilities of typical neuroleptic agents and of thioridazine, clozapine, sulpiride and metoclopramide to antagonise the hyperactivity induced by dopamine applied intracerebrally to areas of the extrapyramidal and mesolimbic systems. Eur J Pharmacol 40: 9–19
Costall B, Naylor RJ (1976b) Antagonism of the hyperactivity induced by dopamine applied intracerebrally to the nucleus accumbens septi by typical neuroleptics and by clozapine, sulpiride and thioridazine. Eur J Pharmacol 35: 161–168
Costall B, Fortune DH, Naylor RJ, Mardsen CD, Pycock C (1975) Serotonergic involvement with neuroleptic catalepsy. Neuropharmacology 14: 859–868
Coward D, Dixon K, Enz A, Shearman G, Urwyler S, White T, Karobath M (1989) Partial brain dopamine D2 receptor agonists in the treatment of schizophrenia. Psychopharmacol Bull 25: 393–397
Crow TJ, Johnstone EC, Deakin JF, Longden A (1976) Dopamine and schizophrenia. Lancet 2: 563–566
Csernansky JG, Wrona CT, Bardgett ME, Early TS, Newcomer JW (1993) Subcortical dopamine and serotonin turnover during acute and subchronic administration of typical and atypical neuroleptics. Psychopharmacology 110: 145–151
Daly DA, Moghaddam B (1993) Actions of clozapine and haloperidol on the extracellular levels of excitatory amino acids in the prefrontal cortex and striatum of conscious rats. Neurosci Lett 152: 61–64
Davidson M, Kahn RS, Stern RG, Hirschowitz J, Apter S, Knott P, Davis KL (1993) Treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia. Psychiatry Res 46: 151–163
Delini-Stula A, Berdah-Tordjman D, Neumann N (1992) Partial benzodiazepine agonists in schizophrenia: expectations and present clinical findings. Clin Neuropharmacol 15 [Suppl 1 Pt A]: 405A-406A
Den Boer JA, Ravelli DP, Huisman J, Ohrvik J, Verhoeven WM, Westenberg HG (1990) Double blind comparative study of remoxipride and haloperidol in acute schizophrenic patients. Psychopharmacology 102: 76–84
Deo R, Soni S, Rastogi SC, Levine S, Plant I, Edwards JG, Mitchell M, Chanas A (1990) Remoxipride and haloperidol in the acute phase of schizophrenia: a double-blind comparison. Acta Psychiatr Scand Suppl 358: 120–124
Deutch AY (1994) Identification of the neural systems subserving the actions of clozapine: clues from immediate-early gene expression. J Clin Psychiatry 55 [9, suppl B]: 37–42
Deutch AY, Moghaddam B, Innis RB, Krystal JH, Aghajanian GK, Bunney BS, Charney DS (1991) Mechanisms of action of atypical antipsychotic drugs. Implications for novel therapeutic strategies for schizophrenia. Schizophr Res 4: 121–156
Deutch AY, Bourdelais AJ, Zahm DS (1993) The nucleus accumbens core and shell: accumbal compartments and their functional attributes. In: Kalivas PW, Barnes CD (eds) Limbic circuits and neuropsychiatry. CRC Press, Boca Raton, pp 45–88
Dewey SL, Smith GS, Logan J, Alexoff D, Ding YS, King P, Papas N, Brodie JD, Ashby CR (1995) Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J Neurosci 15: 821–829
Diaz J, Levesque D, Griffon N, Lammers CH, Martres MP, Sokoloff P, Schwartz JC (1994) Opposing roles for dopamine D-2 and D-3 receptors on neurotensin mRNA expression in nucleus accumbens. Eur J Neurosci 6: 1384–1387
Domeney AM, Arnt J, Costall B, Naylor RJ, Sanchez C, Smith AG (1994) Effect of sertindole on raised mesolimbic dopaminergic activity in the rat. Drug Dev Res 31: 175–185
Drago J, Gerfen CR, Lachowicz JE, Steiner H, Hollon TR, Love PE, Ooi GT, Grinberg A, Lee EJ, Huang SP et al. (1994) Altered striatal function in a mutant mouse lacking D1A dopamine receptors. Proc Natl Acad Sci USA 91: 12564–12568
Drescher K, Hetey L (1988) Influence of antipsychotics and serotonin antagonists on presynaptic receptors modulating the release of serotonin in synaptosomes of the nucleus accumbens of rats. Neuropharmacology 27: 31–36
Drew KL, O'Connor WT, Kehr J, Ungerstedt U (1990) Regional specific effects of clozapine and haloperidol on GABA and dopamine release in rat basal ganglia. Eur J Pharmacol 187: 385–397
Duinkerke SJ, Botter PA, Jansen AA, van Dongen PA, van Haaften AJ, Boom AJ, van Laarhoven JH, Busard HL (1993) Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial. Br J Psychiatry 163: 451–455
Duval F, Mokrani MC, Macher JP, Crocq MA, Castro JO, Bailey P, Lataste X (1993) Neuroendocrine profile of SDZ HDC-912 and OPC-4392, 2 new atypical antipsychotic drugs, in schizophrenic patients. Psychopharmacology 110: 177–180
Edwards E, Ashby CR Jr, Wang RY (1991) The effect of typical and atypical antipsychotic drugs on the stimulation of phosphoinositide hydrolysis produced by the 5-HT3 receptor agonist 2-methyl-serotonin. Brain Res 545: 276–278
Egan MF, Karoum F, Wyatt RJ (1991) Effects of acute and chronic clozapine and haloperidol administration on 3-methoxytyramine accumulation in rat prefrontal cortex, nucleus accumbens and striatum. Eur J Pharmacol 199: 191–199
Egan MF, Hurd Y, Hyde TM, Weinberger DR, Wyatt RJ, Kleinman JE (1994) Alterations in mRNA levels of D2 receptors and neuropeptides in striatonigral and striatopallidal neurons of rats with neuroleptic-induced dyskinesias. Synapse 18: 178–189
Ellenbroek BA, Prinssen EPM, Cools AR (1994) The role of serotonin receptor subtypes in the behavioural effects of neuroleptic drugs — a paw test study in rats. Eur J Neurosci 6: 1–8
Esposito E, Pagannone S, Prisco S (1993) Serotonin-dopamine interaction in the rat ventral tegmental area: an electrophysiological study in vivo. Soc Neurosci Abstr 19: 1372
Fabre LF, Arvanitis L, the Seroquel Study Group (1993) A multicenter, open, pilot trial of ICI 204,636 in hospitalized patients with acute psychotic symptomatology. Presented at the ACNP Annual Meeting, San Juan, PR
Factor SA, Brown D, Molho ES, Podskalny GD (1994) Clozapine — a 2 year open trial in Parkinson's disease patients with psychosis. Neurology 44: 544–546
Farde L (1992) Selective D1- and D2-dopamine receptor blockade both induces akathisia in humans — a PET study with [11C]SCH 23390 and [11C]raclopride. Psychopharmacology 107: 23–29
Farde L, Nordstrom AL (1992) PET analysis indicates atypical central dopamine receptor occupancy in clozapine-treated patients. Br J Psychiatry Suppl 17: 30–33
Farde L, Wiesel F-A, Nordstrom A-L, Sedvall G (1989) D1 and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology 99: S28-S31
Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538–544
Farde L, Nyberg S, Nordstrom A-L, Halldin C, Sedvall G (1993) Dopamine and serotonin receptor occupancy examined by PET in antipsychotic drug treated patients. Presented at the American College of Neuropsychopharmacology 32nd Annual Meeting, Honolulu, Hawaii
Fibiger HC, Robertson GS (1992) Neuroleptic-induced c-fos expression in the forebrain: contrasting effects of typical and atypical neuroleptics. Presented at the ACNP Annual Meeting, San Juan, PR
Fink H, Morgenstern R, Oelssner W (1984) Clozapine — a serotonin antagonist? Pharmacol Biochem Behav 20:513–517
Fink-Jensen A, Hansen L, Nielsen PG, Nielsen EB (1993) Clozapine, risperidone and sertindole preferentially increase interstitial DOPAC levels in the rat prefrontal cortex relative to dorsolateral striatum. Soc Neurosci Abstr 19:81
Fink-Jensen A, Kristensen P (1994) Effects of typical and atypical neuroleptics on Fos protein expression in the rat forebrain. Neurosci Lett 182:115–118
Fischman LG (1983) Dreams, hallucinogenic drug states, and schizophrenia: a psychological and biological comparison. Schizophr Bull 9:73–94
Fishman RHB, Feigenbaum JJ, Yanai J, Klawans HL (1983) The relative importance of dopamine and norepinephrine in mediating locomotor activity. Prog Neurobiol 20:55–88
Fitzgerald LW, Deutch AY, Gasic G, Heinemann SF, Nestler EJ (1995) Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs. J Neurosci 15 [3 Pt 2]: 2453–2461
Flamez A, Debacker JP, Wilczak N, Vauquelin G, Dekeyser J (1994) [3H]clozapine is not a suitable radioligand for the labelling of D-4 dopamine receptors in postmortem human brain. Neurosci Lett 175:17–20
Fog R (1975) Neuroleptic action of clozapine injected into various brain are as in rats. Int Pharmacopsychiatry 10:89–93
Freedman R, Kirch D, Bell J, Adler LE, Pecevich M, Pachtman E, Denver P (1982) Clonidine treatment of schizophrenia: double-blind comparison to placebo and neuroleptic drugs. Acta Psychiatr Scand 65:35–45
Friedman A (1978) [Pizotifen (Sandomigran) used in the treatment of parkinsonian tremor (preliminary communication)] Neurol Neurochir Pol 12:263–267
Friedman E, Gianutsos G, Kuster J (1983) Chronic fluphenazine and clozapine elicit opposite changes in brain muscarinic receptor binding: implications for understanding tardive dyskinesia. J Pharmacol Exp Ther 226:7–12
Friedman L, Knutson L, Shurell M, Meltzer HY (1991) Prefrontal sulcal prominence is inversely related to response to clozapine in schizophrenia. Biol Psychiatry 29:865–877
Fuxe K, Eneroth P, Gustafsson JA, Lofstrom A, Skett P (1977) Dopamine in the nucleus accumbens: preferential increase of DA turnover by rat prolactin. Brain Res 122:177–182
Gainetdinov RR, Grekhova TV, Sotnikova TD, Rayevsky KS (1994) Dopamine D-2 and D-3 receptor preferring antagonists differentially affect striatal dopamine release and metabolism in conscious rats. Eur J Pharmacol 261:327–331
Gallager DW, Aghajanian GK (1976) Effect of antipsychotic drugs on the firing of dorsal raphe cells. I. Role of adrenergic system. Eur J Pharmacol 39:341–355
Gallipoli PZ, Clark J, Amara S, Deutch AY (1993) Haloperidol and clozapine differentially regulate GABA transporter mRNAs in the prefrontal cortex of the rat. Soc Neurosci Abstr 19:1214
Gardner EL (1992) Neuroanatomical specificity of action of the atypical antipsychotics. In: Lindenmayer JP, Kay SR (eds) New biological vistas on schizophrenia. Brunner/Mazel, New York, pp 158–181
Gardner EL, Walker LS, Paredes W (1993) Clozapine's functional mesolimbic selectivity is not duplicated by the addition of anticholinergic action to haloperidol — a brain stimulation study in the rat. Psychopharmacology 110:119–124
Gattaz WF, Gattaz D, Beckmann H (1982) Glutamate in schizophrenics and healthy controls. Arch Psychiatr Nervenkr 231:221–225
Gattaz WF, Schummer B, Behrens S (1994) Effects of zotepine, haloperidol and clozapine on MK-801-induced stereotypy and locomotion in rats. J Neural Transm [Gen Sect] 96:227–232
Gelders Y, VandenBussche G, Reyntjens A, Janssen P (1986) Serotonin-S2 receptor blockers in the treatment of chronic schizophrenia. Clin Neuropharmacol 9:325–327
Gellman RL, Aghajanian GK (1994) Serotonin(2) receptor-mediated excitation of interneurons in piriform cortex — antagonism by atypical antipsychotic drugs. Neuroscience 58:515–525
Gerbaldo H, Demisch L, Lehmann CO, Bochnik J (1988) The effect of OPC-4392, a partial dopamine receptor agonist on negative symptoms: results of an open study. Pharmacopsychiatry 21:387–388
Gerfen CR, Engbar TM (1992) Molecular neuroanatomic mechanisms of Parkinson's disease: a proposed therapeutic approach. Neurol Clin 10:435–449
Gerlach J, Casey DE (1990) Remoxipride, a new selective D2 antagonist, and haloperidol in cebus monkeys. Prog Neuropsychopharmacol Biol Psychiatry 14:103–112
Gerlach J, Hansen L (1993) Effect of chronic treatment with NNC 756, a new D-1 receptor antagonist, or raclopride, a D-2 receptorantagonist, in drug-naive Cebus monkeys: dystonia, dyskinesia and D-1/D-2 supersensitivity. J Psychopharmacol 7:355–364
Gervais J, Rouillard C (1993) Electrophysiological responses of mesencephalic dopamine neurons to dorsal raphe stimulation in 5-HT-depleted rats. Soc Neurosci Abstr 19:1372
Gianutsos G, Moore KE (1977) Dopaminergic supersensitivity in striatum and olfactory tubercle following chronic administration of haloperidol or clozapine. Life Sci 20 [9]:1585–1591
Glatt CE, Snowman AM, Sibley DR, Snyder SH (1995) Clozapine: Selective labeling of sites resembling 5HT6 serotonin receptors may reflect psychoactive profile. Mol Med 1:398–406
Gnegy ME, Lucchelli A, Costa E (1977) Correlation between drug-induced supersensitivity of dopamine dependent striatal mechanisms and the increase in striatal content of the Ca2+ regulated protein activator of cAMP phosphodiesterase. Naunyn Schmiedebergs Arch Pharmacol 301:121–127
Goldberg TE, Weinberger DR (1994) The effects of clozapine on neurocognition: an overview. J Clin Psychiatry 55 [Suppl B]:88–90
Goldberg TE, Gold JM, Weinberger DR (1993a) A comparison of the effects of clozapine and haloperidol on the cognition of patients with schizophrenia. Soc Neurosci Abstr 19:856
Goldberg TE, Greenberg RD, Griffin SJ, Gold JM, Kleinman JE, Pickar D, Schulz SC, Weinberger DR (1993b) The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry 162:43–48
Goldman-Rakic PS, Lidow MS, Gallager DW (1990) Overlap of dopaminergic, adrenergic, and serotoninergic receptors and complementarity of their subtypes in primate prefrontal cortex. J Neurosci 10:2125–2138
Goldstein JM, Litwin LC (1988) Spontaneous activity of A9 and A10 dopamine neurons after acute and chronic administration of the selective dopamine D-1 receptor antagonist SCH 23390. Eur J Pharmacol 155:175–180
Goldstein JM, Litwin LC, Sutton EB, Malick JB (1993) Seroquel: electrophysiological profile of a potential atypical antipsychotic. Psychopharmacology 112:293–298
Grace AA (1991) Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41:1–24
Grace AA (1992) The depolarization block hypothesis of neuroleptic action: implications for the etiology and treatment of schizophrenia. J Neural Transm Suppl 36:91–131
Graham SR, Kokkinidis L (1993) Clozapine inhibits limbic system kindling: implications for antipsychotic action. Brain Res Bull 30:597–605
Green AI, Alam MY, Sobieraj JT, Pappalardo KM, Waternaux C, Salzman C, Schatzberg AF, Schildkraut JJ (1993) Clozapine response and plasma catecholamines and their metabolites. Psychiatry Res 46:139–49
Greene P, Cote L, Fahn S (1993) Treatment of drug-induced psychosis in Parkinson's disease with clozapine. Adv Neurol 60:703–706
Groppetti A, Parenti M, Galli CL, Bugatti A, Cattabeni F, Di Giulio AM, Racagni G (1978) 3-Methoxytyramine and different neuroleptics: dissociation from HVA and DOPAC. Life Sci 23:1763–1768
Gudelsky GA, Nash JF, Berry SA, Meltzer HY (1989) Basic biology of clozapine: electrophysiological and neuroendocrinological studies. Psychopharmacology 99 [Suppl]: S13-S17
Guinetdinov RR, Bogdanov MB, Kudrin VS, Rayevsky KS (1994) Remoxipride and raclopride differ from metoclopramide by their effects on striatal dopamine release and biosynthesis in rats. Neuropharmacology 33:215–219
Gumulka W, Kostowski W, Czlonkowski A (1973) Role of 5-HT in the action of some drugs affecting extrapyramidal system. Pharmacology 10:363–372
Gunne LM, Andren PE (1993) An animal model for coexisting tardive dyskinesia and tardive Parkinsonism — a glutamate hypothesis for tardive dyskinesia. Clin Neuropharmacol 16:90–95
Guo N, Robertson GS, Fibiger HC (1992) Scopolamine attenuates haloperidol-induced c-fos expression in the striatum. Brain Res 588:164–167
Gupta SK, Mishra RK (1992) Effects of chronic treatment of haloperidol and clozapine on levels of G-protein subunits in rat striatum. J Mol Neurosci 3:197–201
Gygi SP, Gibb JW, Hanson GR (1994) Differential effects of antipsychotic and psychotomimetic drugs on neurotensin systems of discrete extrapyramidal and limbic regions. J Pharmacol Exp Ther 270:192–197
Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY (1993) Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 34:702–712
Halperin R, Guerin JJ Jr, Davis KL (1989) Regional differences in the induction of behavioral supersensitivity by prolonged treatment with atypical neuroleptics. Psychopharmacology 98:386–391
Hand TH, Hu XT, Wang RY (1987a) Differential effects of acute clozapine and haloperidol on the activity of ventral tegmental (A10) and nigrostriatal (A9) dopamine neurons. Brain Res 415:257–269
Hand TH, Kasser RJ, Wang RY (1987b) Effects of acute thioridazine, metoclopramide and SCH 23390 on the basal activity of A9 and A10 dopamine cells. Eur J Pharmacol 137:251–255
Hashimoto T, Kitamura N, Kajimoto Y, Shirai Y, Shirakawa O, Mita T, Nishino N, Tanaka C (1993) Differential changes in serotonin 5-HT(1A) and 5-HT(2) receptor binding in patients with chronic schizophrenia. Psychopharmacology 112 [1 Suppl]:S35-S39
Hauber W (1993) Clozapine improves dizocilpine-induced delayed alternation impairment in rats. J Neural Transm [Gen Sect] 94:223–233
Heal DJ, Czudek C, Buckett WR (1994) Common Profile of D1 receptor antagonists and atypical antipsychotic drugs revealed by analysis of dopamine turnover. Prog Neuropsychophormocol Biol Psychiatry 18:803–821
Heilig M, Engel JA, Soderpalm B (1993) In vivo antisense blockade of c-fos-expression in the nucleus accumbens prevents the locomotor stimulant action of systemic cocaine in rats. Soc Neurosci Abstr 19:1857
Hernandez L, Hoebel BG (1989) Haloperidol given chronically decreases basal dopamine in the prefrontal cortex more than the striatum or nucleus accumbens as simultaneously measured by microdialysis. Brain Res Bull 22:763–769
Hicks PB (1990) The effect of serotonergic agents on haloperidol-induced catalepsy. Life Sci 47:1609–1615
Hietala J, Lappalainen J, Koulu M, Syvalahti E (1990) Dopamine D1 receptor antagonism in schizophrenia: is there reduced risk of extrapyramidal side-effects? Trends Pharmacol Sci 11:406–410
Hietala J, Koulu M, Kuoppamaki M, Lappalainen J, Syvalahti E (1992) Chronic clozapine treatment down-regulates serotonin 5-HT-1c receptors in rat brain. Prog Neuropsychopharmacol Biol Psychiatry 16:727–732
Hildebrand J, Delecluse F (1987) Effect of ritanserin, a selective serotonin-S2 antagonist, on parkinsonian rest tremor. Curr Ther Res 41:298–300
Hiroi N, Graybiel AM (1993) Typical and atypical neuroleptics stimulate contrasting patterns of neuropeptide and Fos/FRA expression in the striatum. Soc Neurosci Abstr 19:129
Hjorth S, Carlsson A, Wikstrom H, Lindberg P, Sanchez D, Hacksell U, Arvidsson LE, Svensson U, Nilsson JL (1981) 3-PPP, a new centrally acting DA-receptor agonist with selectivity for autoreceptors. Life Sci 28:1225–1238
Hoffman DC (1992) Typical and atypical neuroleptics antagonize MK-801-induced locomotion and stereotypy in rats. J Neural Transm [Gen Sect] 89:1–10
Hollerman JR, Abercrombie ED, Grace AA (1992) Electrophysiological, biochemical, and behavioral studies of acute haloperidol-induced depolarization block of nigral dopamine neurons. Neuroscience 47:589–601
Hommer DW, Zahn TP, Pickar D, van Kammen DP (1984) Prazosin, a selective alpha1-noradrenergic receptor antagonist, has no effect on symptoms but increases autonomic arousal in schizophrenic patients. Psychiatry Res 11:193–204
Hornykiewicz O (1982) Brain catecholamines in schizophrenia — a good case for noradrenaline. Nature 299:484–486
Hoyberg OJ, Fensbo C, Remvig J, Lingjaerde O, Slothnielsen M, Salvesen I (1993) Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand 88:395–402
Hoyer D, Gozlan H, Bolanos F, Schechter LE, Hamon M (1989) Interaction of psychotropic drugs with central 5-HT3 recognition sites: fact or artifact? Eur J Pharmacol 171:137–139
Huff RM, Adams RN (1980) Dopamine release in n. accumbens and striatum by clozapine: simultaneous monitoring by in vivo electrochemistry. Neuropharmacology 19:587–590
Hyttel J, Larsen J-J, Christensen AV, Arnt J (1985) Receptor-binding profiles of neuroleptics. In: Casey DE, Chase TN, Christensen AV, Gerlach J (eds) Dyskinesia — research and treatment. Springer, Berlin, pp 9–18
Ichikawa J, Meltzer HY (1990a) The effect of chronic clozapine and haloperidol on basal dopamine release and metabolism in rat striatum and nucleus accumbens studied by in vivo microdialysis. Eur J Pharmacol 176:371–374
Ichikawa J, Meltzer HY (1990b) Apomorphine does not reverse reduced basal dopamine release in rat striatum and nucleus accumbens after chronic haloperidol treatment. Brain Res 507:138–142
Ikeguchi K, Kuroda A (1995) Mianserin treatment of patients with psychosis induced by antiparkinsonian drugs. Eur Arch Psychiatr Clin Neurosci 244:320–324
Imperato A, Angelucci L (1989) The effects of clozapine and fluperlapine on the in vivo release and metabolism of dopamine in the striatum and in the prefrontal cortex of freely moving rats. Psychopharmacol Bull 25:383–389
Invernizzi RW, Cervo L, Samanin R (1988) 8-Hydroxy-2-(di-n-propylamino) tetralin, a selective serotonin1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis. Neuropharmacology 27:515–518
Invernizzi R, Pozzi L, Samanin R (1995a) Further studies on the effects of chronic clozapine on regional extracellular dopamine levels in the brain of conscious rats. Brain Res 670:165–168
Invernizzi R, Pozzi L, Samanin R (1995b) Selective reduction of extracellular dopamine in the rat nucleus accumbens following chronic treatment with DAU 6215, a 5-HT3 receptor antagonist. Neuropharmacology 34:211–215
Iversen LL, Horn AS, Miller RJ (1975) Structure-activity relationships for agonist and antagonist drugs at pre- and postsynaptic dopamine receptor sites in rat brain. In: Usdin E, Bunney WE (eds) Pre- and postsynaptic receptors. Marcel Dekker, New York, pp 207–243
Iversen SD (1992) Glycine NMDA antagonists: novel antipsychotic drugs? Presented at American College of Neuropsychopharmacology, 31st Annual Meeting, San Juan, PR
Jaber M, Tison F, Fournier MC, Bloch B (1994) Differential influence of haloperidol and sulpiride on dopamine receptors and peptide messenger RNA Levels in the rat striatum and pituitary. Mol Brain Res 23:14–20
Janowsky A, Neve KA, Kinzie JM, Taylor B, de Paulis T, Belknap JK (1992) Extrastriatal dopamine D2 receptors: distribution, pharmacological characterization and region-specific regulation by clozapine. J Pharmacol Exp Ther 261:1282–1290
Janssen PAJ, Awouters FHL (1994) Is it possible to predict the clinical effects of neuroleptics from animal data? 5. From haloperidol and pipamperone to risperidone. Arzneimittelforschung 44-1:269–277
Janssen PAJ, Niemegeers CJC, Jageneau AHM (1960) Apomorphine-antagonism in rats. Arzneimittelforschung 10:1003–1005
Janssen PAJ, Niemegeers CJE, Schellekens KHL (1965) Is it possible to predict the clinical effects of neuroleptic drugs (major tranquilizers) from animal data? Arzneimittelforschung 15:104–117
Janssen PAJ, Van Bever WFM (1978) Structure-activity relationships of the butyrophenones and diphenylbutylpiperidines. In: Iversen LL, Iversen SD, Snyder SH (eds) Handbook of psychopharmacology, volume 10. Plenum Press, New York, pp 1–35
Janssen PAJ, Niemegeers CJ, Awouters F, Schellekens KH, Megens AA, Meert TF (1988) Pharmacology of risperidone (R 64, 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 244:685–693
Jaskiw GE, Hussain G, Meltzer HY (1993) Frontal cortex lesions modify the cataleptogenic properties of haloperidol but not of clozapine. Biol Psychiatry 34:188–190
Javitt DC, Zukin SR (1990) The role of excitatory amino acids in neuropsychiatric illness. J Neuropsychiatr Clin Neurosci 2:44–52
Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP (1994) Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 151:1234–1236
Jenner P, Rupniak NM, Marsden CD (1985) Differential alteration of striatal D-1 and D-2 receptors induced by the long-term administration of haloperidol, sulpiride or clozapine to rats. Psychopharmacology 2:174–181
Jerlicz M, Kostowski W, Bidzinski A, Hauptmann M (1978) Effects of lesions in the ventral noradrenergic bundle on behavior and response to psychotropic drugs in rats. Pharmacol Biochem Behav 9:721–724
Johnson SW, Seutin V, North RA (1992) Burst firing in dopamine neurons induced byN-methyl-d-aspartate: role of electrogenic sodium pump. Science 258:665–667
Jolicoeur FB, Gagne MA, Rivest R, Drumheller A, Stpierre S (1993) Atypical neuroleptic-like behavioral effects of neurotensin. Brain Res Bull 32:487–491
Kafetzopoulos E (1986) Effects of amphetamine and apomorphine on locomotor activity after kainic acid lesion of the nucleus accumbens septi in the rat. Psychopharmacology 88:271–274
Kahn RS, Davidson M, Knott P, Stern RG, Apter S, Davis KL (1993a) Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Arch Gen Psychiatry 50:599–605
Kahn RS, Siever L, Davidson M, Greenwald C, Moore C (1993b) Haloperidol and clozapine treatment and their effect onm-chlorophenylpiperazine-mediated responses in schizophrenia — implications for the mechanism of action of clozapine. Psychopharmacology 112 [1 Suppl]:S90-S94
Kahn RS, Davidson M, Siever LJ, Sevy S, Davis KL (1994) Clozapine treatment and its effect on neuroendocrine responses induced by the serotonin agonist,m-chlorophenylpiperazine. Biol Psychiatry 35:909–912
Kalivas PW, Duffy P (1989) Similar effects of daily cocaine and stress on mesocorticolimbic dopamine neurotransmission in the rat. Biol Psychiatry 25:913–928
Kalivas PW, Richardson-Carlson R, Van-Orden G (1986) Cross-sensitization between foot shock stress and enkephalin-induced motor activity. Biol Psychiatry 21:939–950
Kane J, Honigfeld G, Singer J, Meltzer H, the Clozaril Collaborative Study Group (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789–796
Karbe H, Wienhard K, Hamacher K, Huber M, Herholz K, Coenen HH, Stocklin G, Lovenich A, Heiss WD (1991) Positron emission tomography with [18F] methylspiperone demonstrates D2 dopamine receptor binding differences of clozapine and haloperidol. J Neural Transm [Gen Sect] 86:163–173
Karler R, Calder LD, Thai LH, Bedingfield JB (1995) The dopaminergic, glutamatergic, GABAergic bases for the action of amphetamine and cocaine. Brain Res 671:100–104
Karlsson P, Smith L, Farde L, Harnryd C, Wiesel FA, Sedvall GC (1994) Lack of apparent antipsychotic effect of the dopamine D1-receptor antagonist SCH 39166 in schizophrenia. Neuropsychopharmacology 10 [3S/Part 2]:32S
Karoum F, Egan MF (1992) Dopamine release and metabolism in the rat frontal cortex, nucleus accumbens, and striatum: a comparison of acute clozapine and haloperidol. Br J Pharmacol 105:703–707
Karoum F, Chrapusta SJ, Egan MF (1994) 3-Methoxytyramine is the major metabolite of released dopamine in the rat frontal cortex: Reassessment of the effects of antipsychotics on the dynamics of dopamine release and metabolism in the frontal cortex, nucleus accumbens, and striatum by a simple two pool model. J Neurochem 63:972–979
Kathmann M, Schlicker E, Gothert M (1994) Intermediate affinity and potency of clozapine and low affinity of other neuroleptics and of antidepressants at H-3 receptors. Psychopharmacology 116:464–468
Keller HH, Bartholini G, Pletscher A (1973) Increase of 3-methoxy-4-hydroxyphenylethylene glycol in rat brain by neuroleptic drugs. Eur J Pharmacol 23:183–186
Kelly PH, Iversen SD (1976) Selective 60HDA-induced destruction of mesolimbic dopamine neurons: abolition of psychostimulant-induced locomotor activity in rats. Eur J Pharmacol 40:45–56
Kelly PH, Seviour PW, Iversen SD (1975) Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. Brain Res 94:507–522
Kilts CD, Anderson CM, Bissette G, Ely TD, Nemeroff CB (1988) Differential effects of antipsychotic drugs on the neurotensin concentration of discrete rat brain nuclei. Biochem Pharmacol 37:1547–1554
Kim JS, Claus D, Kornhuber HH (1983) Cerebral glutamate, neuroleptic drugs and schizophrenia: increase of cerebrospinal fluid glutamate levels and decrease of striate body glutamate levels following sulpiride treatment in rats. Eur Neurol 22:367–370
Kinkead B, Owens MJ, Nemeroff CB (1993) The effects of sertindole on regional CNS neurotensin concentrations in the rat brain. Soc Neurosci Abstr 19:856
Kinon BJ (1993) The influence of extrastriatal dopamine metabolism on haloperidol-induced catalepsy. Biol Psychiatry 33:132A
Knable MB, Hyde TM, Egan MF, Tosayali M, Wyatt RJ, Kleinman JE (1994) Quantitative autoradiography of striatal dopamine D1, D2 and re-uptake sites in rats with vacuous chewing movements. Brain Res 646:217–222
Kobayashi RM, Fields JZ, Hruska RE, Beaumont K, Yamamura HI (1978) Brain neurotransmitter receptors and chronic antipsychotic drug treatment: a model for tardive dyskinesia. In: Usdin E (ed) Animal models in psychiatry. Pergamon Press, New York, pp 405–409
Kohler C, Ogren SO, Haglund L, Angeby T (1979) Regional displacement by sulpiride of [3H]spiperone binding in vivo. Biochemical and behavioural evidence for a preferential action of limbic and nigral dopamine receptors. Neurosci Lett 13:51–56
Kohler C, Haglund L, Ogren SO, Angeby T (1981) Regional blockade by neuroleptic drugs of in vivo3H-spiperone binding in the rat brain. Relation to blockade of apomorphine induced hyperactivity and stereotypies. J Neural Transm 52:163–173
Korsgaard S, Gerlach J, Christensson E (1985) Behavioral aspects of serotonin-dopamine interaction in the monkey. Eur J Pharmacol 118:245–252
Korsgaard S, Noring U, Povlsen UJ, Gerlach J (1986) Effects of citalopram, a specific serotonin uptake inhibitor, in tardive dyskinesia and parkinsonism. Clin Neuropharmacol 9:52–57
Kostowski W, Gumulka W, Cxlonkowski A (1972) Reduced cataleptogenic effects of some neuroleptics in rats with lesioned midbrain raphe and treated withp-chlorophenylalanine. Brain Res 48:443–446
Kretschmer BD, Winterscheid B, Danysz W, Schmidt WJ (1994) Glycine site antagonists abolish dopamine D2 but not D1 receptor mediated catalepsy in rats. J Neural Transm [Gen Sect] 95:123–136
Krystal JH, Seibyl JP, Price LH, Woods SW, Heninger GR, Aghajanian GK, Charney DS (1993)m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Evidence implicating serotonergic systems in the positive symptoms of schizophrenia. Arch Gen Psychiatry 50:624–635
Kubota T (1993) Neuroleptic malignant syndrome induced by nemonapride. Acta Neurol Napoli 15:142–144
Kulikov AV, Kozlachkova EY, Popova NK (1992) Activity of tryptophan hydroxylase in brain of hereditary predisposed to catalepsy rats. Pharmacol Biochem Behav 43:999–1003
Kulikov AV, Kolpakov VG, Maslova GB, Kozintsev I, Popova NK (1994) Effect of selective 5-HT1A agonists and 5-HT2 antagonists on inherited catalepsy in rats. Psychopharmacology 114:172–174
Kulikov AV, Avgustinovich DF, Kolpakov VG, Maslova GB, Popova NK (1995a) 5-HT2A serotonin receptors in the brain of rats and mice hereditarily predisposed to catalepsy. Pharmacol Biochem Behav 50:383–387
Kulikov AV, Kozlachkova EY, Kudryavtseva NN, Popova NK (1995b) Correlation between tryptophan hydroxylase activity in the brain and predisposition to pinch-induced catalepsy in mice. Pharmacol Biochem Behav 50:431–435
Kuoppamaki M, Seppala T, Syvalahti E, Hietala J (1993) Chronic clozapine treatment decreases 5-hydroxytryptamine1C receptor density in the rat choroid plexus — comparison with haloperidol. J Pharmacol Exp Ther 264:1262–1267
Labie C, Saubusse P, Keane PE, Lefur G, Soubrie P (1995) Effects of the alpha receptor ligand SR 31742A on neurotensin biosynthesis in rat basal ganglia. Synapse 19:241–246
Lader M (1988) Beta-adrenoceptor antagonists in neuropsychiatry: an update. J Clin Psychiatry 49:213–223
Laduron PM, Janssen PF, Leysen JE (1978) Spiperone: a ligand of choice for neuroleptic receptors. 2. Regional distribution and in vivo displacement of neuroleptic drugs. Biochem Pharmacol 27:317–321
Lahti RA, Evans DL, Stratman NC, Figur LM (1993) Dopamine-D(4) versus dopamine D(2) receptor selectivity of dopamine receptor antagonists — possible therapeutic implications. Eur J Pharmacol 236:483–486
Lai H, Carino MA, Sperry R, Horita A (1980) Effects of thioridazine on apomorphine-elicited stereotypic behavior and motor activity. Pharmacol Biochem Behav 13:397–401
Lane RF, Blaha CD (1986) Electrochemistry in vivo: application to CNS pharmacology. Ann NY Acad Sci 473:50–69
Lane RF, Blaha CD (1987) Acute thioridazine stimulates mesolimbic but not nigrostratal dopamine release: demonstration by in vivo electrochemistry. Brain Res 408:317–320
Lane RF, Blaha CD, Rivet JM (1988) Selective inhibition of mesolimbic dopamine release following chronic administration of clozapine: involvement of alpha 1-noradrenergic receptors demonstrated by in vivo voltammetry. Brain Res 460:398–401
Lang A, Vasar E, Soosaar A, Harro J (1992) The involvement of sigma and phencyclidine receptors in the action of antipsychotic drugs. Pharmacol Toxicol 71:132–138
Lapierre YD, Nair NP, Chouinard G, Awad AG, Saxena B, Jones B, McClure DJ, Bakish D, Max P, Manchanda R (1990) A controlled dose-ranging study of remoxipride and haloperidol in schizophrenia — a Canadian multicentre trial. Acta Psychiatr Scand Suppl 358:72–77
Lappalainen J, Hietala J, Koulu M, Syvalahti E (1990) Neurochemical effects of chronic co-administration of ritanserin and haloperidol: comparison with clozapine effects. Eur J Pharmacol 190:403–407
Laux G, Klieser E, Schroder HG, Dittmann V, Unterweger B, Schubert H, Konig P, Schony HW, Bunse J, Beckmann H (1990) A double-blind multicentre study comparing remoxipride, two and three times daily, with haloperidol in schizophrenia. Acta Psychiatr Scand Suppl 358:125–129
Lawrence MS, Redmond DE Jr, Elsworth JD, Taylor JR, Roth RH (1991) The D1 receptor antagonist, SCH 23390, induces signs of parkinsonism in African green monkeys. Life Sci 49:PL229-PL234
Le Fur G, Burgevin MC, Malgouris C, Uzan A (1979) Differential effects of typical and atypical neuroleptics on alpha-noradrenergic and dopaminergic post synaptic receptors. Neuropharmacology 18:591–594
Lee T, Tang SW (1984) Loxapine and clozapine decrease serotonin (S2) but do not elevate dopamine (D2) receptor numbers in the rat brain. Psychiatry Res 12:277–285
Lejeune F, Audinot V, Gobert A, Rivet JM, Spedding M, Millan MJ (1994) Clozapine inhibits serotoninergic transmission by an action at alpha(1)-adrenoceptors not at 5-HT(1A) receptors. Eur J Pharmacol 260:79–83
Leslie RA, Moorman JM, Coulson A, Grahame-Smith DG (1993) Serotonin2/1C receptor activation causes a localized expression of the immediate-early gene c-fos in rat brain: evidence for involvement of dorsal raphe nucleus projection fibres. Neuroscience 53 [2]:457–463
Lew MF, Waters CH (1993) Clozapine treatment of parkinsonism with psychosis. J Am Geriatr Soc 41:669–671
Leysen JE, Van Gompel P, de Chaffoy de Courcelles D, Niemegeers CJ (1987) Opposite regulation of serotonin-S2 and dopamine-D2 receptors in rat brain following chronic receptor blockade. J Recept Res 7:223–239
Li D, Simmons RM, Lyengar S (1993) CCKB receptors tonically modulate A10 dopaminergic neurons selectively: neurochemical evaluation of LY288513. Soc Neurosci Abstr 19:1547
Lichter JB, Barr CL, Kennedy JL, Van Tol HH, Kidd KK, Livak KJ (1993) A hypervariable segment in the human dopamine receptor D4 (DRD4) gene. Hum Mol Genet 2:767–773
Lidow MS, Goldman-Rakic PS (1994) A common action of clozapine, haloperidol, and remoxipride on D-1- and D-2-dopaminergic receptors in the primate cerebral cortex. Proc Natl Acad Sci 91:4353–4356
Lidow MS, Goldman-Rakic PS, Gallager DW, Rakic P (1991) Distribution of dopaminergic receptors in the primate cerebral cortex: quantitative autoradiographic analysis using [3H]raclopride, [3H]spiperone and [3H]SCH23390. Neuroscience 40:657–671
Lidsky TI, Yablonskyalter E, Zuck L, Banerjee SP (1993) Anti-glutamatergic effects of clozapine. Neurosci Lett 163:155–158
Lieberman JA (1993) Understanding the mechanism of action of atypical antipsychotic drugs. A review of compounds in use and development. Br J Psychiatry Suppl [22]:7–18
Lieberman JA, Alvir JMJ, Woerner M, Degreef G, Bilder RM, Ashtari M, Bogerts B, Mayerhoff DI, Geisler SH, Loebel A, Levy DL, Hinrichsen G, Szymanski SR, Chakos M, Koreen A, Borenstein M, Kane JM (1992) Prospective study of psychobiology in first-episode schizophrenia at Hillside Hospital. Schizophr Bull 18:351–371
Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A, Kronig M, Bookstein P, Kane JM (1994) Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 151: 1744–1752
Lindstrom LH (1994) Long-term clinical and social outcome studies in schizophrenia in relation to the cognitive and emotional side effects of antipsychotic drugs. Acta Psychiatr Scand 89 [Suppl. 380]: 74–76
Lindstrom LH, Wieselgren IM, Struwe G, Kristjansson E, Akselson S, Arthur H, Andersen T, Lindgren S, Norman O, Naimell L (1990) A double-blind comparative multicentre study of remoxipride and haloperidol in schizophrenia. Acta Psychiatr Scand Suppl 358: 130–135
Lipska BK, Weinberger DR (1993) Delayed effects of neonatal hippocampal damage on haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat. Dev Brain Res 75: 213–222
Lipska BK, Jaskiw GE, Chrapusta S, Karoum F, Weinberger DR (1992a) Ibotenic acid lesion of the ventral hippocampus differentially affects dopamine and its metabolites in the nucleus accumbens and prefrontal cortex in the rat. Brain Res 585: 1–6
Lipska BK, Jaskiw GE, Phillips I, Weinberger DR (1992b) Developmental effects on dopamine-related behaviors in rats with neonatal excitotoxic hippocampal lesions. Presented at the ACNP Annual Meeting, San Juan, PR
Litman RE, Hong WW, Weissman EM, Su TP, Potter WZ, Pickar D (1993) Idazoxan, an alpha 2 antagonist, augments fluphenazine in schizophrenic patients: a pilot study. J Clin Psychopharmacol 13: 264–267
Litwin LC, Goldstein JM (1994) Effects of neurotensin on mid-brain dopamine neuronal activity. Drug Dev Res 1994 32: 6–12
Ljungberg T, Ungerstedt U (1978) Classification of neuroleptic drugs according to their ability to inhibit apomorphine-induced locomotion and gnawing: evidence for two different mechanisms of action. Psychopharmacology 56: 239–247
Lublin H, Gerlach J, Morkeberg F (1994) Long-term treatment with low doses of the D1 antagonist NNC 756 and the D2 antagonist raclopride in monkeys previously exposed to dopamine antagonists. Psychopharmacology 114: 495–504
Lynch MR (1992) Schizophrenia and the D1 receptor: focus on negative symptoms. Prog Neuropsychopharmacol Biol Psychiatry 16: 797–832
Macciardi F, Petronis A, Vantol HHM, Marino C, Cavallini MC, Smeraldi E, Kennedy JL (1994) Analysis of the D4 dopamine receptor gene variant in an Italian schizophrenia kindred. Arch Gen Psychiatry 51: 288–293
Macgibbon GA, Lawlor PA, Bravo R, Dragunow M (1994) Clozapine and haloperidol produce a differential pattern of immediate early gene expression in rat caudate-putamen, nucleus accumbens, lateral septum and islands of calleja. Mol Brain Res 23: 21–32
Maertens de Noordhout A, Delwaide PJ (1986) Open pilot trial of ritanserin in parkinsonism. Clin Neuropharmacol 9: 480–484
Magnusson O, Fowler CJ, Kohler C, Ogren SO (1986) Dopamine D2 receptors and dopamine metabolism. Relationship between biochemical and behavioural effects of substituted benzamide drugs. Neuropharmacology 25: 187–197
Maidment NT, Marsden CA (1987a) Acute administration of clozapine, thioridazine and metoclopramide increases extracellular DOPAC and decreases extracellular 5-HIAA, measured in the nucleus accumbens and striatum of the rat using in vivo voltammetry. Neuropharmacology 26: 187–193
Maidment NT, Marsden CA (1987b) Repeated atypical neuroleptic administration: effects on central dopamine metabolism monitored by in vivo voltammetry. Eur J Pharmacol 136: 141–149
Maj J, Sowinska H, Baran L, Kapturkiewicz Z (1974) The effects of clozapine, thioridazine and phenoxybenzamine on the action of drugs stimulating the central catecholamine receptors. Pol J Pharmacol Pharm 26: 437–448
Maj J, Sarnek J, Klimek V, Rawlow A (1976) On the anticataleptic action of cyproheptadine. Pharmacol Biochem Behav 5: 201–205
Malmberg A, Jackson DM, Eriksson A, Mohell N (1993) Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B, and D3 receptors. Mol Pharmacol 43: 749–754
Marder SR (1992) Risperidone: clinical development: north American results. Clin Neuropharmacol 15 [Suppl 1 Pt A]: 92A-93A
Marder SR, Meibach RC (1994) Risperidone in the treatment of schizophrenia. Am J Psychiatry 151:825–835
Marin C, Parashos SA, Kapitzoglou-Logothetis V, Peppe A, Chase TN (1993) D1 and D2 dopamine receptor-mediated mechanisms and behavioral supersensitivity. Pharmacol Biochem Behav 45: 195–200
Marwood JF (1994) Influence of alpha 1-adrenoceptor antagonism of ketanserin on the nature of its 5-HT2 receptor antagonism. Clin Exp Pharmacol Physiol 21: 955–961
Matsubara S, Meltzer HY (1989) Effect of typical and atypical antipsychotic drugs on 5-HT2 receptor density in rat cerebral cortex. Life Sci 45: 1397–1406
Matsubara S, Matsubara R, Kusumi I, Koyama T, Yamashita I (1993) Dopamine D1, D2 and serotonin2 receptor occupation by typical and atypical antipsychotic drugs in vivo. J Pharmacol Exp Ther 265: 498–508
Matsumoto M, Hidaka K, Tada S, Tasaki Y, Yamaguchi T (1995) Polymorphic tandem repeats in dopamine D4 receptor are spread over primate species. Biochem Biophys Res Commun 207: 467–475
McAllister G, Knowles MR, Wardbooth SM, Sinclair HA, Patel S, Marwood R, Emms F, Patel S, Smith A, Seabrook GR, Freedman SB (1995) Functional coupling of human D-2, D-3, and D-4 dopamine receptors in HEK293 cells. J Recept Signal Transduct Res 15: 267–281
McCreadie RG, Todd N, Livingston M, Eccleston D, Watt JA, Herrington RN, Tait D, Crocket G, Mitchell MJ, Huitfeldt B (1990) A double-blind comparative study of remoxipride and thioridazine in the acute phase of schizophrenia. Acta Psychiatr Scand Suppl 358: 136–137
McEvoy JP, Hogarty GE, Steingard S (1991) Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 48: 739–745
McEvoy J, Borison R, Small J, van Kammen D, Meltzer H, Hammer M, Morris D, Shu V, Sebree T, Grebb J, Kashin K (1993) The efficacy and tolerability of setindole in schizophrenic patients: a pilot, double-blind, placebo-controlled, dose-ranging study. Presented at the ACNP Annual Meeting, San Juan, PR
McMillen BA, Scott SM, Davanzo EA (1988) Reversal of neuroleptic-induced catalepsy by novel aryl-piperazine anxiolytic drugs. J Pharm Pharmacol 40: 885–887
McPherson SE, Loo P, Braunwalder A, Wood PL (1987) Enhancement of the in vivo binding of [3H]flunitrazepam by the atypical neuroleptic, clozapine. Neuropharmacology 26: 265–269
Meco G, Marini S, Lestingi L, Linfante I, Modarelli FT, Agnoli A (1988) Controlled single-blind crossover study of ritanserin and placebo inl-dopa-induced dyskinesias in Parkinson's disease. Curr Ther Res 43: 262–270
Meco G, Alessandria A, Bonifati V, Giustini P (1994) Risperidone for hallucinations in levodopa-treated Parkinson's disease patients. Lancet 343: 1370–1371
Megens AAHP, Awouters FHL, Schotte A, Meert TF, Dugovic C, Niemegeers CJE, Leysen JE (1994) Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology 114: 9–23
Mehta AK, Ticku MK (1990) Role ofN-methyl-d-aspartate (NMDA) receptors in experimental catalepsy in rats. Life Sci 46: 37–42
Meltzer HY (1991) The mechanism of action of novel antipsychotic drugs. Schizophr Bull 17: 263–287
Meltzer HY (1994) (cited within) J Clin Psychiatry (Monograph Series) 12 [2]: 23
Meltzer HY, Matsubara S, Lee JC (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251: 238–246
Meltzer HY, Burnett S, Bastani B, Ramirez LF (1990) Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Commun Psychiatry 41: 892–897
Mendis T, Mohr E, George A, Rusk IN, Gray P, Grimes JD (1994) Symptomatic relief from treatment-induced psychosis in Parkinson's disease — an open-label pilot study with remoxipride. Move Disord 9: 197–200
Menon MK, Gordon LI, Fitten J (1988) Interaction between clozapine and a lipophilic alpha 1-adrenergic agonist. Life Sci 43: 1791–1804
Merchant KM, Dorsa DM (1993) Differential induction of neurotensin and c-fos gene expression by typical versus atypical antipsychotics. Proc Natl Acad Sci USA 90: 3447–3451
Merchant KM, Miller MA (1994) Coexpression of neurotensin and C-fos mRNAs in rat neostriatal neurons following acute haloperidol. Mol Brain Res 23: 271–277
Merchant KM, Dobie DJ, Dorsa DM (1992a) Expression of the proneurotensin gene in the rat brain and its regulation by antipsychotic drugs. Ann NY Acad Sci 668: 54–69
Merchant KM, Dobner PR, Dorsa DM (1992b) Differential effects of haloperidol and clozapine on neurotensin gene transcription in rat neostriatum. J Neurosci 12: 652–663
Mercugliano M, Chesselet MF (1992) Clozapine decreases enkephalin mRNA in rat striatum. Neurosci Lett 136: 10–14
Meshul CK, Stallbaumer RK, Taylor B, Janowsky A (1994) Haloperidol-induced morphological changes in striatum are associated with glutamate synapses. Brain Res 648: 181–195
Metysova J, Protiva M (1975) Proceedings: stereospecificity of neuroleptic effects in the 10-piperazino-10, 11-dihydrodibenzo (b, f) thiepin series. Act Nerv Super (Praha) 17: 218–219
Miller RJ, Hiley CR (1974) Anti-muscarinic properties of neuroleptics and drug-induced Parkinsonism. Nature 248: 596–597
Min SK, Rhee CS, Kim CE, Kang DY (1993) Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial. Yonsei Med J 34: 179–190
Minabe Y, Ashby CR Jr, Wang RY (1991) The CCK-A receptor antagonist devazepide but not the CCK-B receptor antagonist L-365,260 reverses the effects of chronic clozapine and haloperidol on midbrain dopamine neurons. Brain Res 549: 151–154
Mita T, Hanada S, Nishino N, Kuno T, Nakai H, Yamadori T, Mizoi Y, Tanaka C (1986) Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics. Biol Psychiatry 21: 1407–1414
Moghaddam B, Bunney BS (1990) Acute effect of typical and atypical antipsychotic drugs on the release of dopamine from the prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J Neurochem 54: 1755–1760
Mohammed AK, Danysz W, Ogren SO, Archer T (1986) Central noradrenaline depletion attenuates amphetamine-induced locomotor behavior. Neurosci Lett 64: 139–144
Moore NA, Tye NC, Axton MS, Risius FC (1992) The behavioral pharmacology of olanzapine, a novel atypical antipsychotic agent. J Pharmacol Exp Ther 262: 545–551
Moore NA, Rees G, Sanger G, Tye NC (1994) Effects of olanzapine and other antipsychotic agents on responding maintained by a conflict schedule. Behav Pharmacol 5: 196–202
Moore S, Kenyon P (1994) Atypical antipsychotics, clozapine and sulpiride do not antagonise amphetamine-induced stereotyped locomotion. Psychopharmacology 114: 123–130
Muller-Spahn F (1992) Risperidone in the treatment of chronic schizophrenic patients: an international double-blind parallel-group study versus haloperidol. The International Risperidone Research Group. Clin Neuropharmacol 15 [Suppl 1 Pt A]: 90A-91A
Murray AM, Hyde TM, Knable MB, Herman MM, Bigelow LB, Carter JM, Weinberger DR, Kleinman JE (1995) Distribution of putative D4 dopamine receptors in postmortem striatum from patients with schizophrenia. J Neurosci 15: 2186–2191
Nakra BRS, Bond AJ, Lader HM (1975) Comparative effects of metoclopramide and prochlorperazine in normal subjects. J Clin Pharmacol 15: 449–454
Neal-Beliveau BS, Joyce JN, Lucki I (1993) Serotonergic involvement in haloperidol-induced catalepsy. J Pharmacol Exp Ther 265: 207–217
Newcomer JW, Faustman WO, Zipursky RB, Csernansky JG (1992) Zacopride in schizophrenia: a single-blind serotonin type 3 antagonist trial. Arch Gen Psychiatry 49: 751–752
Nguyen TV, Kosofsky BE, Birnbaum R, Cohen BM, Hyman SE (1992) Differential expression of c-fos and zif268 in rat striatum after haloperidol, clozapine, and amphetamine. Proc Natl Acad Sci USA 89: 4270–4274
Nomikos GG, Iurlo M, Andersson JL, Kimura K, Svensson TH (1994) Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex. Psychopharmacology 115: 147–156
Nordstrom AL, Farde L, Halldin C (1993) High 5-HT(2) Receptor occupancy in clozapine treated patients demonstrated by PET. Psychopharmacology 110: 365–367
Nordstrom Al, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G (1995) D1, D2, and 5HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 152: 1444–1449
Nothen MM, Cichon S, Hemmer S, Hebebrand J, Remschmidt H, Lehmkuhl G, Poustka F, Schmidt M, Catalano M, Fimmers R, Korner J, Rietschel M, Propping P (1994) Human dopamine D4 receptor gene: frequent occurrence of a null allele and observation of homozygosity. Hum Mol Genet 3: 2207–2212
Nyberg S, Farde L, Eriksson L, Halldin C, Eriksson B (1993a) 5-HT(2) and D(2) dopamine receptor occupancy in the living human brain — a PET study with risperidone. Psychopharmacology 110: 265–272
Nyberg S, Halldin C, Bertilsson L, Farde L (1993b) D2 occupancy and clinical state in schizophrenic patients on depot neuroleptics. Presented at the American College of Neuropsychopharmacology, 32nd Annual Meeting, Honolulu, Hawaii
O'Connor WT, Drew KL, Ungerstedt U (1989) Differences in dopamine release and metabolism in rat striatal subregions following acute clozapine using in vivo microdialysis. Neurosci Lett 98: 211–216
O'Dell SJ, LaHoste GJ, Widmark CB, Shapiro RM, Potkin SG, Marshall JP (1990) Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serotonin receptors in rat brain. Synapse 6: 146–153
Ogren SO, Archer T (1994) Effects of typical and atypical antipsychotic drugs on two-way active avoidance — relationship to dopamine receptor blocking profile. Psychopharmacology 114: 383–391
Ogren SO, Fuxe K (1988) D1- and D2-receptor antagonist induce catalepsy via different efferent striatal pathways. Neurosci Lett 85: 333–338
Ogren SO, Hall H, Kohler C (1978) Studies on the stereoselective dopamine receptor blockade in the rat brain by rigid spiro amines. Life Sci 23: 1769–1773
Ogren SO, Archer T, Johansson C (1983) Evidence for a selective brain noradrenergic involvement in the locomotor stimulant effects of amphetamine in the rat. Neurosci Lett 43: 327–331
Ogren SO, Hall H, Kohler C, Magnusson O, Lindbom LO, Angeby K, Florvall L (1984) Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain. Eur J Pharmacol 102: 459–474
Ogren SO, Hall H, Kohler C, Magnusson O, Florvall L (1985) [Selective antidopaminergic properties of remoxiprid, a new potential antipsychotic agent] Die selektiven antidopaminergen Eigenschaften von Remoxiprid, einem neuen moglichen antipsychotischen Wirkstoff. Arzneimittelforschung 35: 1227–1231
Ogren SO, Hall H, Kohler C, Magnusson O, Sjostrand SE (1986) The selective dopamine D2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions. Psychopharmacology 90:287–294
Olbrich R, Schanz H (1988) The effect of the partial dopamine agonist terguride on negative symptoms in schizophrenics. Pharmacopsychiatry 21: 389–390
Ongur D, Deutch AY (1993) Mediodorsal thalamic lesions differentially regulate dopamine metabolism in prefrontal cortical subfields and nucleus accumbens compartments. Soc Neurosci Abstr 19: 1214
Overton P, Clark D (1992a) Iontophoretically administered drugs acting at theN-methyl-D-aspartate receptor modulate burst firing in A9 dopamine neurons in the rat. Synapse 10: 131–140
Overton P, Clark D (1992b) Electrophysiological evidence that intrastriatally administeredN-methyl-D-aspartate augments striatal dopamine tone in the rat. J Neural Transm [Park Dis Dement Sect] 4: 1–14
Owen RR Jr, Gutierrez-Esteinou R, Hsiao J, Hadd K, Benkelfat C, Lawlor BA, Murphy DL, Pickar D (1993) Effects of clozapine and fluphenazine treatment on responses tom-chlorophenylpiperazine infusions in schizophrenia. Arch Gen Psychiatry 50: 636–644
Owens DGC, Harrisonread PE, Johnstone EC (1994)L-Dopa helps positive but not negative features of neuroleptic-insensitive chronic schizophrenia. J Psychopharmacol 8: 204–212
Parashos SA, Marin C, Chase TN (1989) Synergy between a selective D1 antagonist and a selective D2 antagonist in the induction of catalepsy. Neurosci Lett 105: 169–173
Patris M, Agussol P, Alby JM, Brion S, Burnat G, Castelnau D, Deluermoz S, Dufour H, Ferreri M, Goudemand M (1990) A double-blind multicentre comparison of remoxipride, at two dose levels, and haloperidol. Acta Psychiatr Scand Suppl 358: 78–82
Peacock L, Lublin H, Gerlach J (1990) The effects of dopamine D1 and D2 receptor agonists and antagonists in monkeys withdrawn from long-term neuroleptic treatment. Eur J Pharmacol 186: 49–59
Pearce RK, Seeman P, Jellinger K, Tourtellotte WW (1990) Dopamine uptake sites and dopamine receptors in Parkinson's disease and schizophrenia. Eur Neurol 30 [Suppl 1]: 9–14
Pickar D, Owen RR, Litman RE, Konicki E, Gutierrez R, Rapaport MH (1992) Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine. Arch Gen Psychiatry 49: 345–353
Piercey MF, Broderick PA, Hoffmann WE, Vogelsang GD (1990) U-66444B and U-68553B, potent autoreceptor agonists at dopaminergic cell bodies and terminals. J Pharmacol Exp Ther 254: 369–374
Pijnenburg A, Honig W, van Rossum J (1975) Inhibition ofd-amphetamine induced locomotor activity by injection of haloperidol into the nucleus accumbens septi of the rat. Psychopharmacologia 41: 87–95
Pilowsky LS, Costa DC, Ell PJ, Murray RM, Verhoeff NP, Kerwin RW (1992) Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia. Lancet 340: 199–202
Pinter MM, Helscher RJ (1993) Therapeutic Effect of clozapine in psychotic decompensation in idiopathic Parkinson's Disease. J Neural Transm [Parkinsons] 5: 135–146
Pires JG, Ramage AG, Silva SR, Futuro Neto HA (1993a) Effects of the 5-HT receptor antagonists cyanopindolol, ICI 169,369, cisapride and granisetron on neuroleptic-induced catalepsy in mice. Braz J Med Biol Res 26: 847–852
Pires JG, Silva SR, Ramage AG, Futuro-Neto-HA (1993b) Influence of median raphe nucleus lesions on neuroleptic-induced catalepsy and on the anticataleptic effect of buspirone. Braz J Med Biol Res 26: 323–326
Pirot S, Godbout R, Mantz J, Tassin JP, Glowinski J, Thierry AM (1992) Inhibitory effects of ventral tegmental area stimulation on the activity of prefrontal cortical neurons: evidence for the involvement of both dopaminergic and GABAergic components. Neuroscience 49: 857–865
Popova NK, Kulikov AV, Kolpakov VG, Barykina NN, Alekhina TA (1985) [Changes in the serotonin system of the brains of rats genetically predisposed to catalepsy] Izmeneniia v serotoninovoi sisteme mozga krys, geneticheski predraspolozhennykh k katalepsii. Zh Vyssh Nerv Deiat 35: 742–746
Povlsen UJ, Noring U, Laursen AL, Korsgaard S, Gerlach J (1986) Effects of serotonergic and anticholinergic drugs in haloperidol-induced dystonia in Cebus monkeys. Clin Neuropharmacol 9: 84–90
Prinssen EP, Ellenbroek BA, Stamatovic B, Cools AR (1993) The effects of haloperidol and raclopride in the paw test are influenced similarly by SCH 39166. Eur J Pharmacol 231: 275–280
Prinssen EPM, Ellenbroek BA, Cools AR (1994a) Peripheral and central adrenoceptor modulation of the behavioural effects of clozapine in the paw test. Br J Pharmacol 112: 769–774
Prinssen EPM, Ellenbroek BA, Cools AR (1994b) Combined antagonism of adrenoceptors and dopamine and 5-HT receptors underlies the atypical profile of clozapine. Eur J Pharmacol 262: 167–170
Prisco S, Pagannone S, Esposito E (1994) Serotonin-dopamine interaction in the rat ventral tegmental area: an electrophysiological study in vivo. J Pharmacol Exp Ther 271: 83–90
Qin ZH, Zhou LW, Weiss B (1994) D2 dopamine receptor messenger RNA is altered to a greater extent by blockade of glutamate receptors than by blockade of dopamine receptors. Neuroscience 60: 97–114
Racagni G, Bruno F, Bugatti A, Parenti M, Apud JA, Santini V, Carenzi A, Groppetti A, Cattabeni F (1980) Behavioral and biochemical correlates after haloperidol and clozapine long-term treatment. Adv Biochem Psychopharmacol 24: 45–51
Ramirez OA, Wang RY (1986) Locus coeruleus norepinephrine-containing neurons: effects produced by acute and subchronic treatment with antipsychotic drugs and amphetamine. Brain Res 362: 165–170
Rao TS, Contreras PC, Cler JA, Emmett MR, Mick SJ, Iyengar S, Wood PL (1991) Clozapine attenuatesN-methyl-D-aspartate receptor complex-mediated responses in vivo: tentative evidence for a functional modulation by a noradrenergic mechanism. Neuropharmacology 30: 557–565
Rasmussen K, Stockton ME, Czachura JF, Howbert JJ (1991) Cholecystokinin (CCK) and schizophrenia: the selective CCKB antagonist LY262691 decreases midbrain dopamine unit activity. Eur J Pharmacol 209: 135–138
Rasmussen K, Czachura JF, Stockton ME, Howbert JJ (1993) Electrophysiological effects of diphenylpyrazolidinone cholecystokinin-B and cholecystokinin-A antagonists on midbrain dopamine neurons. J Pharmacol Exp Ther 264: 480–488
Rayevsky KS, Gainetdinov RR, Kharlamov A (1993) Typical and atypical neuroleptics differentially affect striatal dopamine release and metabolism studied by microdialysis in freely moving rats. Soc Neurosci Abstr 19: 1065
Rebec GV, Gelman J, Alloway KD, Bashore TR (1983) Cataleptogenic potency of the antipsychotic drugs is inversely correlated with neuronal activity in the amygdaloid complex of the rat. Pharmacol Biochem Behav 19: 759–763
Reynolds GP, Mason SL (1994) Are striatal dopamine D-4 receptors increased in schizophrenia?. J Neurochem 63: 1576–1577
Reynolds GP, Garrett NJ, Rupniak N, Jenner P, Marsden CD (1983) Chronic clozapine treatment of rats down-regulates cortical 5-HT2 receptors. Eur J Pharmacol 89: 325–326
Riblet LA, Taylor DP, Eison MS, Stanton HC (1982) Pharmacology and neurochemistry of buspirone. J Clin Psychiatry 43: 11–18
Richelson E (1984) Neuroleptic affinities for human brain receptors and their use in predicting adverse effects. J Clin Psychiatry 45: 331–336
Richelson E, Nelson A (1984) Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro. Eur J Pharmacol 103: 197–204
Rivest R, Marsden CA (1992) Differential effects of amfonelic acid on the haloperidol- and clozapine-induced increase in extracellular DOPAC in the nucleus accumbens and the striatum. Synapse 10: 71–78
Robertson A, MacDonald C (1984) Atypical neuroleptics clozapine and thioridazine enhance amphetamine-induced stereotypy. Pharmacol Biochem Behav 21: 97–101
Robertson GS, Fibiger HC (1992) Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 46: 315–328
Robertson GS, Pfaus JG, Atkinson LJ, Matsumura H, Phillips AG, Fibiger HC (1991) Sexual behavior increases c-fos expression in the forebrain of the male rat. Brain Res 564: 352–357
Robertson GS, Vincent SR, Fibiger HC (1992) D1 and D2 dopamine receptors differentially regulate c-fos expression in striatonigral and striatopallidal neurons. Neuroscience 49: 285–296
Rodrigues AA, Jansen FP, Leurs R, Timmerman H, Prell GD (1995) Interaction of clozapine with the histamine H-3 receptor in rat brain. Br J Pharmacol 114: 1523–1524
Rogue PJ, Vincendon G, Malviya AN (1993) Differential induction of early genes in the CNS by typical and atypical neuroleptics. Soc Neurosci Abstr 19:1260
Rosse RB, Theut SK, Banay-Schwartz M, Leighton M, Scarcella E, Cohen CG, Deutsch SI (1989) Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an openlabel, pilot study. Clin Neuropharmacol 12: 416–424
Rosse RB, Schwartz BL, Leighton MP, Davis RE, Deutsch SI (1990) An open-label trial of milacemide in schizophrenia: an NMDA intervention strategy. Clin Neuropharmacol 13: 348–354
Roth BL, Ciaranello RD (1991) Chronic mianserin treatment decreases 5-HT2 receptor binding without altering 5-HT2 receptor mRNA levels. Eur J Pharmacol 207: 169–172
Roth BL, Ciaranello RD, Meltzer HY (1992) Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors. J Pharmacol Exp Ther 260: 1361–1365
Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ, Shen Y, Meltzer HY, Sibley DR (1994) Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268: 1403–1410
Roth RH, Bacopoulos NG, Bustos G, Redmond DE Jr (1980) Antipsychotic drugs: differential effects on dopamine neurons in basal ganglia and mesocortex following chronic administration in human and nonhuman primates. Adv Biochem Psychopharmacol 24: 513–520
Rubinstein JE, Hitzemann RJ, Ashby CR, Wang RY (1989) Long-term treatment with antipsychotics does not alter the phosphoinositide response to muscarinic or D2 dopaminergic agonists in rat striatum. Brain Res 496: 385–388
Ruch W, Asper H, Burki HR (1976) Effect of clozapine on the metabolism of serotonin in rat brain. Psychopharmacologia 46: 103–109
Rupniak NM, Kilpatrick G, Hall MD, Jenner P, Marsden CD (1984) Differential alterations in striatal dopamine receptor sensitivity induced by repeated administration of clinically equivalent doses of haloperidol, sulpiride or clozapine in rats. Psychopharmacology 84: 512–519
Rupniak NM, Hall MD, Mann S, Fleminger S, Kilpatrick G, Jenner P, Marsden CD (1985) Chronic treatment with clozapine, unlike haloperidol, does not induce changes in striatal D-2 receptor function in the rat. Biochem Pharmacol 34: 2755–2763
Safferman AZ, Lieberman JA, Pollack S, Kane JM (1993) Akathisia and clozapine treatment. J Clin Psychopharmacol 13: 286–287
Sanberg PR (1980) Haloperidol induced catalepsy is mediated by postsynaptic dopamine receptors. Nature 284: 472–473
Sayers AC, Burki HR, Ruch W, Asper H (1975) Neuroleptic-induced hypersensitivity of striatal dopamine receptors in the rat as a model of tardive dyskinesias: effects of clozapine, haloperidol, loxapine and chlorpromazine. Psychopharmacologia 41: 97–104
Schmidt CJ, Sullivan CK, Fadayel GM (1994) Blockade of striatal 5-hydroxytryptamine(2) receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine. J Neurochem 62: 1382–1389
Schmidt WJ, Krahling H, Ruhland M (1987) Antagonism of AP-5- and amphetamine-induced behaviour by timelotem as compared with clozapine and haloperidol. Life Sci 41: 1909–1914
Schmidt WJ, Krahling H, Ruhland M (1991) Antagonism of AP-5-induced sniffing stereotypy links umespirone to atypical antipsychotics. Life Sci 48: 499–505
Schotte A, de Bruyckere K, Janssen PF, Leysen JE (1989) Receptor occupancy by ritanserin and risperidone measured using ex vivo autoradiography. Brain Res 500: 295–301
Schotte A, Janssen PFM, Megens AAHP, Leysen JE (1993) Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res 631: 191–202
Schremmer C, Morgenstern R, Fink H, Ott T (1990) Atypical neuroleptics suppress dopaminergic behavioral supersensitivity. Psychopharmacology 100 [3]: 399–403
Sebens JB, Koch T, Terhorst GJ, Korf J (1995) Differential Fosprotein induction in rat forebrain regions after acute and long-term haloperidol and clozapine treatment. Eur J Pharmacol 273: 175–182
See RE, Ellison G (1990) Comparison of chronic administration of haloperidol and the atypical neuroleptics, clozapine and raclopride, in an animal model of tardive dyskinesia. Eur J Pharmacol 181: 175–186
See RE, Toga AW, Ellison G (1990) Autoradiographic analysis of regional alterations in brain receptors following chronic administration and withdrawal of typical and atypical neuroleptics in rats. J Neural Transm [Gen Sect] 82: 93–109
Seeger TF, Thal L, Gardner EL (1982) Behavioral and biochemical aspects of neuroleptic-induced dopaminergic supersensitivity: studies with chronic clozapine and haloperidol. Psychopharmacology 76: 182–187
Seeman MV, Seeman P (1988) Psychosis and positron tomography. Can J Psychiatry 33: 299–306
Seeman P (1987) Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1: 133–152
Seeman P, Guan HC, Guan HC, Niznik HB (1989a) Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: implications for positron emission tomography of the human brain. Synapse 3: 96–97
Seeman P, Guan H-C, Van Tol HHM (1993) Dopamine D4 receptors elevated in schizophrenics. Nature 365: 441–445
Seeman P, Niznik HB (1990) Dopamine receptors and transporters in Parkinson's disease and schizophrenia. FASEB J 4: 2737–2744
Seeman P, Niznik HB, Guan HC, Booth G, Ulpian C (1989b) Link between D1 and D2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain. Proc Natl Acad Sci USA 86: 10156–10160
Seeman P, Ulpian C (1983) Neuroleptics have identical potencies in human brain limbic and putamen regions. Eur J Pharmacol 94: 145–148
Seeman P, Van Tol HHM (1994) Dopamine receptor pharmacology. Trends Pharmacol Sci 15: 264–270
Seibyl JP, Krystal JH, Price LH, Woods SW, D'Amico C, Heninger GR, Charney DS (1991) Effects of ritanserin on the behavioral, neuroendocrine, and cardiovascular responses to metachlorophenylpiperazine in health human subjects. Psychiatry Res 38: 227–236
Selemon LD, Goldman-Rakic PS (1990) Topographic intermingling of striatonigral and striatopallidal neurons in the rhesus monkey. J Comp Neurol 297: 359–376
Sesack SR, Pickel VM (1992) Prefrontal cortical efferents in the rat synapse on unlabeled neuronal targets of catecholamine terminals in the nucleus accumbens septi and on dopamine neurons in the ventral tegmental area. J Comp Neurol 320: 145–160
Silver H, Nassar A (1992) Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study. Biol Psychiatry 31: 698–704
Simiand J, Keane PE, Barnouin MC, Keane M, Soubrie P, Le Fur G (1993) Neuropsychopharmacological profile in rodents of SR 57746A, a new, potent 5-HT1A receptor agonist. Fundam Clin Pharmacol 7: 413–427
Skarsfeldt T (1988a) Differential effects after repeated treatment with haloperidol, clozapine, thioridazine and tefludazine on SNC and VTA dopamine neurones in rats. Life Sci 42: 1037–1044
Skarsfeldt T (1988b) Effect of chronic treatment with SCH 23390 and haloperidol on spontaneous activity of dopamine neurones in substantia nigra pars compacta (SNC) and ventral tegmental area (VTA) in rats. Eur J Pharmacol 145: 239–243
Skarsfeldt T (1992) Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurones in rats: acute and repeated treatment. Synapse 10: 25–33
Skarsfeldt T (1993) Comparison of the effect of substituted benzamides on midbrain dopamine neurones after treatment of rats for 21 days. Eur J Pharmacol 240: 269–275
Skarsfedt T (1994) Comparison of short-term administration of sertindole, clozapine and haloperidol on the inactivation of midbrain dopamine neurons in the rat. Eur J Pharmacol 254: 291–294
Skarsfeldt T, Perregaard J (1990) Sertindole, a new neuroleptic with extreme selectivity on A10 versus A9 dopamine neurones in the rat. Eur J Pharmacol 182: 613–614
Smith RC, Davis JM (1976) Behavioral evidence for supersensitivity after chronic administration of haloperidol, clozapine, and thioridazine. Life Sci 19: 725–731
Snyder SH, Greenberg D, Yamumura HI (1974) Antischizophrenic drugs: affinity for muscarinic cholinergic receptor sites in the brain predicts extrapyramidal effects. J Psychiatr Res 11: 91–95
Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347: 146–151
Sommer SS, Lind TJ, Heston LL, Sobell JL (1993) Dopamine D4 receptor variants in unrelated schizophrenic cases and controls. Am J Med Genet 48: 90–93
Sommermeyer H, De Vry J, Greuel J, Glaser T (1993) Attenuation of haloperidol-induced dopamine release by 8-OH DPAT in the rat: a correlate for the anticataleptic effects of 8-OH-DPAT. Soc Neurosci Abstr 19: 1384
Sommermeyer H, Frielingsdorf J, Knorr A (1995) Effects of prazosin on the dopaminergic neurotransmission in rat brain. Eur J Pharmacol 276: 267–270
Spina E, Dedomenico P, Ruello C, Longobardo N, Gitto C, Ancione M, Dirosa AE, Caputi AP (1994) Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. Int Clin Psychopharmacol 9: 281–285
Stanley M, Wilk S (1980) Acute and chronic effects of haloperidol and clozapine on dopamine metabolism in two dopamine rich areas of the rat brain. Res Commun Psych Psychiat Behav 5: 37–47
Stanley M, Lautin A, Rotrosen J, Gershon S, Kleinberg D (1980) Metoclopramide: antipsychotic efficacy of a drug lacking potency in receptor models. Psychopharmacology 71: 219–225
Stewart BR, Jenner P, Marsden CD (1988) The pharmacological characterisation of pilocarpine-induced purposeless chewing behaviour in the rat. Psychopharmacology 96: 55–62
Stille G, Lauener H, Eichenberger E (1971) The pharmacology of 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo(b,e)(1,4)diazepine (clozapine). Farmaco [Prat] 26: 603–625
Stockmeier CA, DiCarlo JJ, Zhang Y, Thompson P, Meltzer HY (1993) Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. J Pharmacol Exp Ther 266: 1374–1384
Stowe ZN, Bissette G, Nemeroff CB (1991) Neurotensin-dopamine interactions: relevance to schizophrenia and the action of antipsychotic drugs. Yakubutsu Seishin Kodo 11: 49–59
Strupczewski JT, Bordeau KJ, Chiang YL, Glamkowski EJ, Conway PG, Corbett R, Hartman HB, Szewzak MR, Wilmot CA, Helsley GC (1995) 3-[[(Aryloxy)alkyl]piperidinyl]-1,2-benzisoxazoles as D-2/5-HT2 antagonists with potential atypical antipsychotic activity: antipsychotic profile of iloperidone (HP 873). J Med Chem 38: 1119–1131
Sumiyoshi T, Kido H, Sakamoto H, Urasaki K, Suzuki K, Yamaguchi N, Mori H, Shiba K, Yokogawa K (1994a) In vivo dopamine-D-2 and serotonin-5-HT2 receptor binding study of risperidone and haloperidol. Pharmacol Biochem Behav 47: 553–557
Sumiyoshi T, Kido H, Sakamoto H, Urasaki K, Suzuki K, Yamaguchi N, Mori H, Shiba K (1994b) Time course of dopamine(1,2) and serotonin(2) receptor binding of antipsychotics in vivo. Pharmacol Biochem Behav 49: 165–169
Svartengren J, Celander M (1994) The limbic functional selectivity of amperozide is not mediated by dopamine D-2 receptors as assessed by in vitro and in vivo binding. Eur J Pharmacol 254: 73–81
Svensson A, Carlsson A, Carlsson ML (1992) Differential locomotor interactions between dopamine D1/D2 receptor agonists and the NMDA antagonist dizocilpine in monoamine-depleted mice. J Neural Transm [Gen Sect] 90: 199–217
Svensson A, Carlsson ML, Carlsson A (1993) Glutamate in the ventral striatum can affect psychomotor functions in opposite directions depending on the dopaminergic tone. Soc Neurosci Abstr 19: 1582
Svensson A, Carlsson ML, Carlsson A (1994) Glutamatergic neurons projecting to the nucleus accumbens can affect motor functions in opposite directions depending on the dopaminergic tone. Prog Neuropsychopharmacol Biol Psychiatry 18: 1203–1218
Tamminga C, Gerlach J (1987) Neuroleptics and experimental antipsychotics in schizophrenia. In: Meltzer HY (ed) Psychopharmacology: the third generation of Progress. Raven Press, New York, pp 1129–1140
Tamminga CA, Cascella N, Dixon L, Fahouki T, Herting RL (1990) Excitatory amino acid pharmacotherapy in schizophrenia. Presented at the 17th Congress of CINP, Kyoto, Japan
Tamminga CA, Cascella NG, Lahti RA, Lindberg M, Carlsson A (1992) Pharmacologic properties of (-)-3PPP (preclamol) in man. J Neural Transm [Gen Sect] 88: 165–175
Todorova A, Dimpfel W (1994) Multiunit activity from the A9 and A10 areas in rats following chronic treatment with different neuroleptic drugs. Eur Neuropsychopharmacol 4: 491–501
Tucci S, Fernandez R, Baptista T, Murzi E, Hernandez L (1994) Dopamine increase in the prefrontal cortex correlates with reversal of haloperidol-induced catalepsy in rats. Brain Res Bull 35: 125–133
Ugedo L, Grenhoff J, Svensson TH (1989) Ritanserin, a 5-HT2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology 98: 45–50
Uzan A, Le Fur G, Mitrani N, Kabouche M, Donadieu AM (1978) Effects on striatal and mesolimbic dopamine systems of a new potential antipsychotic drug — mezilamine — with weak cataleptogenic properties. Life Sci 23: 261–273
van Kammen DP, Yao J, Gurklis J, O'Connor D, Nofzinger E, Peters JL (1992) CSF noradrenergic activity and sleep EEG in clinically stable schizophrenic patients after haloperidol withdrawal. Clin Neuropharmacol 15 [Suppl 1 Pt A]: 325A-326A
Van Tol HHM, Bunzow JR, Guan H-C, Sunhara RK, Seeman P, Niznik HB, Civelli O (1991) Cloning of the gene for a human dopamine D4 receptor with a high affinity for the antipsychotic clozapine. Nature 350: 610–614
Van Tol HH, Wu CM, Guan HC, Ohara K, Bunzow JR, Civelli O, Kennedy J, Seeman P, Niznik HB, Jovanovic V (1992) Multiple dopamine D4 receptor variants in the human population. Nature 358: 149–152
Wadenberg ML (1992) Antagonism by 8-OH-DPAT, but not ritanserin, of catalepsy induced by SCH 23390 in the rat. J Neural Transm [Gen Sect] 89: 49–59
Wadenberg ML, Cortizo L, Ahlenius S (1994) Evidence for specific interactions between 5-HT1A and dopamine D-2 receptor mechanisms in the mediation of extrapyramidal motor functions in the rat. Pharmacol Biochem Behav 47: 509–513
Waldmeier PC, Delini-Stula AA (1979) Serotonin-dopamine interactions in the nigrostriatal system. Eur J Pharmacol 55: 363–373
Waldmeier PC, Maitre L (1976) On the relevance of preferential increases of mesolimbic versus striatal dopamine turnover for the prediction of antipsychotic activity of psychotropic drugs. J Neurochem 27: 589–597
Walters JR, Roth RH (1976) Dopaminergic neurons: an in vivo system for measuring drug interactions with presynaptic receptors. Naunyn Schmiedeberg's Arch Pharmacol 296: 5–14
Weiss F, Ettenberg A (1986) Comparison of circling induced by unilateral intrastriatal microinjections of haloperidol, clozapine and CCK-8 in rats. Pharmacol Biochem Behav 24: 983–989
Westerink BH (1978) Effect of centrally acting drugs on regional dopamine metabolism. Adv Biochem Psychopharmacol 19: 255–266
Westerink BH, Korf J (1975) Influence of drugs on striatal and limbic homovanillic acid concentration in the rat brain. Eur J Pharmacol 33: 31–40
Westerink BH, Lejeune B, Korf J, Van Praag HM (1977) On the significance of regional dopamine metabolism in the rat brain for the classification of centrally acting drugs. Eur J Pharmacol 42: 179–190
Wettlaufer TA, Camacho F, Corbett R (1993) The atypical antipsychotic agent clozapine antagonizes the MK-801 discriminative stimulus cue. Soc Neurosci Abstr 19: 1391
Wetzel H, Szegedi A, Hain C, Wiesner J, Schlegel S, Benkert O (1995) Seroquel (ICI 204 636), a putative “atypical” antipsychotic, in schizophrenia with positive symptomatology: results of an open clinical trial and changes of neuroendocrinological and EEG parameters. Psychopharmacology 119: 231–238
White FJ, Wang RY (1983) Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 221: 1054–1057
Wiedemann K, Benkert O, Holsboer F (1990) B-HT 920-a novel dopamine autoreceptor agonist in the treatment of patients with schizophrenia. Pharmacopsychiatry 23: 50–55
Wiesel FA, Sedvall G (1975) Effect of antipsychotic drugs on homovanillic acid levels in striatum and olfactory tubercle of the rat. Eur J Pharmacol 30: 364–367
Wiesel FA, Nordstrom AL, Farde L, Eriksson B (1994) An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. Psychopharmacology 114: 31–38
Williams P (1990) An open trial of ondansetron (GR38032F) in the treatment of acute schizophrenia. Schizophr Res 3: 48
Wilmot CA, Szczepanik AM (1989) Effects of acute and chronic treatments with clozapine and haloperidol on serotonin (5-HT2) and dopamine (D2) receptors in the rat brain. Brain Res 487: 288–298
Wolk SI, Douglas CJ (1992) Clozapine treatment of psychosis in Parkinson's disease: a report of five consecutive cases. J Clin Psychiatry 53: 373–376
Wolkin A, Sanfilipo M, Wolf AP, Angrist B, Brodie JD, Rotrosen J (1992) Negative symptoms and hypofrontality in chronic schizophrenia. Arch Gen Psychiatry 49: 959–65
Wood PL, McQuade PS, Etienne P, Lal S, Nair NP (1983) Differential actions of classical and atypical neuroleptics on mouse nigrostriatal neurons. Prog Neuropsychopharmacol Biol Psychiatry 7: 765–768
Woodruff GN, Kelly PH, Elkhawad AO (1976) Effects of dopamine receptor stimulants on locomotor activity of rats with electrolytic or 6-hydroxydopamine-induced lesions of the nucleus accumbens. Psychopharmacologia 47: 195–198
Worms P, Willigens MT, Continsouza-Blanc D, Lloyd KG (1985) The effect of different types of cortical lesions on drug-in-duced catalepsy in rats: a pharmacological analysis. Eur J Pharmacol 113: 53–59
Xu M, Hu XT, Cooper DC, Moratalla R, Graybiel AM, White FJ, Tonegawa S (1994) Elimination of cocaine-induced hyperactivity and dopamine-mediated neurophysiological effects in dopamine D1 receptor mutant mice. Cell 79: 945–955
Yamamoto BK, Cooperman MA (1992) Chronic treatment with antipsychotic drugs differentially affects extracellular concentrations of striatal glutamate and dopamine. Presented at the ACNP Annual Meeting, San Juan, PR
Yamamoto BK, Cooperman MA (1993) Chronic haloperidol alters sub stantia nigra GABA and extracellular glutamate in the striatum. Soc Neurosci Abstr 19: 1623
Yamamoto BK, Cooperman MA (1994) Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J Neurosci 14: 4159–4166
Yen-Koo HC, Balazs T (1980) Detection of dopaminergic supersensitivity induced by neuroleptic drugs in mice. Drug Chem Toxicol 3: 237–247
Young AB, Penney JB (1993) Biochemical and functional organization of the basal ganglia. In: Jankovic J, Tolosa E (eds) Parkinson's disease and movement disorders, 2nd edn. Williams & Wilkins, Baltimore, pp 1–11
Youngren KD, Moghaddam B, Bunney BS, Roth RH (1994) Preferential activation of dopamine overflow in prefrontal cortex produced by chronic clozapine treatment. Neurosci Lett 165: 41–44
Zivkovic G, Guidotti A, Revuelta A, Costa E (1975) Effect of thioridazine, clozapine and other antipsychotics in the kinetic state of tyrosine hydroxylase and on the turnover of dopamine in striatum and nucleus accumbens. J Pharmacol Exp Ther 194: 37–46
Author information
Authors and Affiliations
Additional information
This study was supported by the Mental Health Clinical Research Center for the Study of Schizophrenia (USPHS MH-41960)
Rights and permissions
About this article
Cite this article
Kinon, B.J., Lieberman, J.A. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology 124, 2–34 (1996). https://doi.org/10.1007/BF02245602
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02245602